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CHAPTER 1- INTRODUCTION
In today’s world, the Internet has become a major source from where we receive
information. The number of people who access the Internet for health information has
increased in recent years. Health information has become the third most sought
information on the Internet today (Choi & Lee, 2007). According to the Pew Research
Internet Project (2013), 72% of Internet users in the United States have looked for
health information online in the past year. The Pew Research Internet Project (2013)
also states that women seek out more health information online than their male
counterparts. Furthermore, the Pew Research Internet Project (2013) states that
researching a drug that was being advertised was one of the major types of health
information sought by online users who searched for health information.
In the United States, disseminators of health information not only include the
medical community, but the pharmaceutical community as well. The pharmaceutical
community uses the process of direct-to-consumer pharmaceutical advertising (DTCPA)
to provide information about their drugs directly to the public. “DTCPA can be defined as
an effort (usually via popular media) made by a pharmaceutical company to promote its
prescription products directly to patients” (Ventola, 2011, p. 669). As of 1997,
pharmaceutical companies started using pamphlets, television and the radio to provide
information about their medical products directly to the consumer (Kelly, 2007).
Previously, DTCPA was primarily through print and broadcast media; however, today
pharmaceutical companies are using the Internet as one of their biggest platforms for
DTCPA with almost a billion dollars being spent on Internet DTCPA alone (Liang &
Mackey, 2011). As per data published as recently as 2015, even though pharmaceutical
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companies have reduced their spending on television and radio DTCPA, they increased
their spending on Internet DTCPA by 108.98% from 2005 to 2009 (Mackey, Cuomo &
Liang, 2015).
With the increase in DTCPA through the Internet, many pharmaceutical
companies have set up websites about the medications they manufacture. Internet
DTCPA has numerous concerns that affect the welfare of the general public. One of the
main concerns is that the information on the Internet is often not monitored by the Food
and Drug Administration (FDA) to the same extent of print and broadcast media DTCPA
(Woodlock, 2005). Therefore, individuals who are using the Internet to seek information
about their drugs could become exposed to information that is not regulated and
monitored as tightly as other forms of DTCPA information. DTCPA also tends to
minimize the risks of the product being advertised (Kaphingst , Dejong, Rudd & Daltroy,
2004). Another main concern is the Internet allows information on the websites to reach
a large number of people in a shorter time (Fox, Ward & O’Rourke, 2006). While this
can be viewed as a benefit, in the case of Internet DTCPA, it holds the ability to reach a
wider audience, therefore potentially impacting a larger number of people in a shorter
amount of time with information that is not tightly regulated by the FDA. Moreover, with
health information being widely sought out by consumers, Internet DTCPA also allows
the pharmaceutical companies to reach these consumers directly through their own
websites. This allows the pharmaceutical companies complete freedom to construct
ideas about their products, impart messages to the consumers and shape people’s
attitudes and beliefs about their drug, through advertising. Due to Internet DTCPA being
a relatively new phenomenon that is accompanied by multiple issues such as lack of
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regulation by the FDA, its ability to reach a large number of people of all ages, and its
ability to market prescription medication, the topic of Internet DTCPA certainly warrants
exploration.
In narrowing my dissertation topic, I felt that it was important to focus on a single
product advertised via DTCPA websites: the websites of oral contraceptive pills (OCPs).
Birth control practices remain an important phenomenon that has been studied both by
both medical and sociological researchers, especially through large-scale studies
(Frost, Singh & Finer, 2007; Jones, Mosher & Daniels, 2012). However, when women’s
birth control practices are studied in the sociological literature, the focus is often the use
of birth control by women, along with the factors that influence their contraceptive
choices/decisions. Researchers have less often studied the portrayal of the birth control
itself. The oral contraceptive pill (OCP) commonly known as the pill is the most widely
used form of contraception today among women of child bearing ages. The pill’s
popularity is also on the rise for non-contraceptive purposes, such as managing
menstruation (Jones, 2011). When the pill is being used as a treatment for ‘”menstrual
problems”, women could be adhering to messages about how their menstruation is
problematic. These messages may come from pharmaceutical companies through
DTCPA. The analysis of prescription drug advertising provides an opportunity for us to
begin examining the portrayal of the OCP in online drug advertisements (DTPCA).
Purpose of the study
There are two major categories of OCPs manufactured by pharmaceutical
companies in the United States today: traditional OCPs and extended-cycle OCPs.
Traditional OCPs have existed since the conception of the OCP and they follow the
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standard regimen of the woman taking 21 or 24 pills with hormones, followed by 7 or 4
non-hormone pills. During the time when the woman is on the non-hormone pills, she
experiences a menstrual cycle. Extended-cycle OCPs, such as Seasonale and
Seasonique are taken continuously for a few months, and the woman does not
experience a menstrual cycle on them for at least three months (Bachmann & Kopacz,
2009; Bonnema & Spencer, 2011; Hicks & Rome, 2010).
Upon looking into previous sociological research, I learned that very little
sociological research has been completed that examines the portrayal of OCPs through
DTCPA. Moreover, previous sociological research has displayed an interest in mostly
studying how extended-cycle OCPs are marketed to the public using DTCPA (Gunson,
2007; Mamo & Foskett, 2009). Based on my perusal of existing research on this topic,
there has been no sociological research that has focused on the DTCPA portrayals of
traditional OCPs exclusively.
Even though there were no specific statistics that could be found on the number
of women taking the traditional OCP versus the extended-cycle OCPs, several
traditional OCPs such as YAZ, Loestrin Fe and ORTHO TRI-CYCLEN LO have been on
the list of top selling 200 drugs in the United States for many years (Bartholow, 2013;
Bartholow, 2012; Bartholow, 2011; Bartholow, 2010). Therefore, it is beneficial to see
how such an important drug, which is used by only women, is portrayed and
characterized on the pharmaceutical websites. With the pill being so popular for its
contraceptive and non-contraceptive functions, it is also helpful to analyze how the pill is
being marketed to women online by the pharmaceutical companies that manufacture,
promote, and sell these OCPs. This led me to the first purpose of this study: to
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understand and describe the messages transmitted through the pharmaceutical
websites via Internet DTCPA, which could be important in shaping women’s attitudes
about their bodies and their reproductive functions.
In the medical literature, menstruation is often seen as a problem that needs to
be controlled rather than a significant part of women’s biology (Houppert, 1999;
Fingerson, 2006). Moreover, OCPs are also being used more frequently now than ever
before for their non-contraceptive functions, such as menstrual management. At least
1.5 million American women now take the pill only for the main non-contraceptive
function which is menstrual management (Jones, 2011). When the message is sent to
women that all instances of menstruation are problematic, women who suffer from
serious menstrual ailments which require medical treatment can be overlooked or
minimized (Johnston-Robledo, Barnack & Wares, 2006). Additionally, sociological
literature suggests that DTCPA is a driving force of medicalization, whereby conditions
that are usually benign are now being treated with medicines (Conrad, 2007). This led
me to the second purpose of this study: to investigate and report on how the
medicalization of female bodily processes and functions occurs via the Internet DTCPA
of traditional OCPs. I was interested in exploring whether traditional OCPs are also
portrayed as altering or managing menstruation for the better, via online DTCPA. In
order to attend to this second purpose, I looked to see how menstruation is portrayed on
traditional OCP websites. Looking at how menstruation was portrayed on the websites
not only served as an overall evidence of medicalization but also helped to further an
understanding of how women’s bodily processes are defined as problematic and
negative via Internet DTCPA.
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The two general research questions that guided this study are as follows: (1)
How are traditional OCPs portrayed and characterized on their websites? (2) What
evidence of medicalization is present on the websites of these OCPs? For the purpose
of this study, only the websites of traditional OCPs were examined using a qualitative
content analysis. I analyzed the websites of the following eight traditional OCPs: Beyaz,
Generess Fe, Lo Loestrin Fe, Minastrin 24 Fe, Natazia, ORTHO TRI-CYCLEN LO,
SAFYRAL and YAZ.
Organization of the Dissertation
Chapter One of this dissertation is the introduction chapter. Chapter Two of this
dissertation consists of a review of the existing literature. This chapter also reviews the
theoretical framework of medicalization. Chapter Three of this dissertation outlines the
methodology that was used to conduct the study. It also provides a description of the
coding categories that I examined during data collection and analysis. Chapters Four,
Five and Six provides the results of the study. Chapter Seven is the discussion and
conclusion chapter of this dissertation.
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CHAPTER 2 - LITERATURE REVIEW AND THEORETICAL
FRAMEWORK
This chapter provides a review of the literature which is relevant to this study. In
particular, the objectives of this literature review were the following:
1) To explore the sociological literature on DTCPA
2) To explore the sociological literature on the theory of medicalization
3) To discuss sociological studies conducted to-date exclusively on the DTCPA of
OCPs
Women’s Use of OCPs
Statistics show that the majority of women who are of reproductive age and who
are using a form of contraception often prefer to use a reversible form such as the OCP.
Currently, OCPs are the leading form of contraception used by women who are under
the age of 34 (CDC, 2010). Of the top 200 selling drugs in the United States in 2011
and 2012, two traditional OCPs were on the list: Loestrin 24Fe, and ORTHO TRICYCLEN LO (Bartholow, 2013; Bartholow, 2012). Of the 200 top selling drugs in the
United States in 2010, three traditional OCPs were on the list: Loestrin 24Fe, ORTHO
TRI-CYCLEN LO, and YAZ (Bartholow, 2011). For the year 2009, four traditional OCPs
were on the list of top 200 selling drugs in the United States: Ocella, ORTHO TRICYCLEN LO, YAZ, and Loestrin 24Fe (Bartholow, 2010).
In recent years, the popularity of the pill amongst women has soared further, due
to the non-contraceptive roles it serves as well. The National Center for Health Statistics
gathered data from 7,356 women between the ages of 15-44, through in-person
interviews from 2006-2008. According to Jones (2011), this data, which was then
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published by the Guttmacher Institute states that 58% of women who are currently on
the pill are using it for non-contraceptive reasons along with its main function of
pregnancy prevention. Of these non-contraceptive reasons listed, 31% of the women
were using it for menstrual pain management, and another 28% of the women were
using it for menstrual regulation. Even among women who had never had sexual
intercourse, 9% reported to using OCPs (Jones, 2011). The majority of these women
were using OCPs for menstrual management (43%) and for menstrual pain (57%).
Traditional OCPs consist of 21 days of active pills, followed by a 7 day interval
(Hicks & Rome, 2010). When a woman is on the traditional OCP, she menstruates
during the interval after the active pills are done. In recent years, traditional OCPs have
also become available in a 24/4 regimen (Bachmann & Kopacz, 2009). That regimen
consists of 24 days of active hormone pills and 4 days of hormone-free pills.
Menstruation occurs during the 4 days when the woman is taking the hormone-free pills.
Extended-cycle OCPs are formulated in such a way that menstruation occurs only once
every few months (Bonnema & Spencer, 2011). In 2003, the FDA approved Seasonale,
which is an extended-cycle OCP. Seasonale is a 91-day regimen that has 84-days’
worth of hormones which are taken without any break followed by a 7 day interval when
the woman menstruates (The American Society of Reproductive Medicine, 2008).
Approved by the FDA in 2006, Lybrel is another extended-cycle OCP. Lybrel consists
of 365 days of active pills, therefore, allowing women to skip their menstrual cycle for a
whole year (The American Society of Reproductive Medicine, 2008). Seasonique is
similar to Seasonale, but instead of having 7 placebo pills, it has 7 pills that contain
ethinyl estradiol (The American Society of Reproductive Medicine, 2008).

Lo-
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Seasonique is very similar to Seasonique, and allows for menstruation every three
months (Bonnema & Spencer, 2011). Traditional OCPs work on the female body in a
different manner than extended-cycle oral contraceptives.
History of DTCPA
The United States and New Zealand are the only two countries in the world that
permit DTCPA (Liang & Mackey, 2011). The Food and Drug Administration (FDA) in the
United States is the regulating body of DTCPA of medications. As per the FDA website,
“Direct-to-consumer (DTC) advertising is a relatively new area of prescription drug
promotion”

(http://www.fda.gov/Drugs/ResourcesForYou

/Consumers/Prescription

DrugAdvertising/ucm071964.htm, Retrieved: January 2014). In the past, DTCPA
consisted mostly of television messages and print messages in magazines or
pamphlets available at physician’s offices. Apart from traditional methods such as print
and broadcast television DTCPA, Internet DTCPA has also started to become
increasingly popular recently (Sheehan, 2007).
The Division of Drug Marketing, Advertising and Communications is the wing of
the FDA that currently oversees DTCPA of prescription medications available in the
United States. The code of federal regulations (CFR) was revised in April 2011 and
provides the mandates for prescription drug advertising to the general public. According
to

the

CFR,

modes

of

advertisement

are

now

defined

by

the

FDA

(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.
cfm?CFRPart=202&showFR=1, Retrieved: January 2014) as the following:
Published journals, magazines, other periodicals, and newspapers, and
advertisements broadcast through media such as radio, television, and telephone
communication systems. Brochures, booklets, mailing pieces, detailing pieces,
file cards, bulletins, calendars, price lists, catalogs, house organs, letters, motion
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picture films, film strips, lantern slides, sound recordings, exhibits, literature, and
reprints and similar pieces of printed, audio, or visual matter descriptive of a drug
and references published (FDA, 2011).
Until 1980, pharmaceutical companies advertised drugs only to physicians, thus
allowing physicians to be in complete control of the process. From 1981 to 1996, even
though pharmaceuticals were still advertising drugs to physicians, consumers were
allowed to obtain printed advertisements about the drugs. This led to consumers having
some information about the drug, yet the physicians still held the upper hand in the
knowledge about these drugs (Conrad & Leiter, 2008). It was only in 1997 that the
pharmaceutical industry received permission to advertise drugs directly to the public
(Kelly, 2007). In 1997, it was decided by the FDA that pharmaceuticals could market a
medication with its name, specific uses, and the symptoms or illnesses it can treat using
broadcast media direct to consumers, rather than just print media. This led to a surge in
advertising of drugs on television. However, with the advancement of the Internet into
American homes in the late 1990s, DTCPA of prescription drugs through the Internet
started rising in popularity (Conrad & Leiter, 2008).
In 2003, pharmaceutical companies spent 59 million dollars on Internet DTPCA
alone (Choi & Lee, 2007). The main reason for this surge in Internet DTCPA is the
popularity of the Internet for many people who are seeking health and pharmaceutical
information online. Health information is the third most sought out subject on the
Internet (Choi & Lee, 2007).

Moreover, among adults aged 18 and above, higher

numbers of women used the Internet for obtaining and looking at health information
when compared to men (Cohen & Adams, 2011). The Internet now serves as another
important and popular platform for DTCPA, along with traditional methods of DTCPA.
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Concerns Surrounding DTCPA
From a sociological perspective, numerous concerns surround DTCPA. DTCPA
represents a marketing technique that aids companies in selling a serious product, such
as medication, under the banner of informing the consumer of serious educational
information (Wolfe, 2002). Moreover, there is concern that the information presented
during DTCPA can often be confusing to the average person, who might not be fully
aware of the scientific and medical terminology used during DTCPA (Kastner, 2005;
Wolfe, 2002). In a study that looked at three television direct-to-consumer
pharmaceutical advertisements, fifty adults who had a limited understanding of the topic
were asked about their understanding of the advertisements. The study showed that
risk information was not understood properly by the participants who had watched the
three television advertisements (Kaphingst et al., 2004). Furthermore, people’s
educational levels and ability to retain information are different. Therefore, how an
individual retains the information given through DTCPA, along with the message they
receive, can be completely varied (Wilkes, Bell & Kravitz, 2000).
Additionally, DTCPA information is often advertised in such a way that often
minimizes the risks of the medication (Hollon, 2005; Kritz, 2008). When there are
commercials on television promoting a particular drug, less time is given to the
discussion of risks when compared to the discussion of the benefits of the drug (Kritz,
2008). In a study of print advertisements that were part of DTCPA, it was found that
benefit information was presented more clearly than risk information. The study also
found that double the amount of benefit information was made available compared to
the amount of risk information that was made available. Moreover, the study found that
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risk information was presented as harder to read when compared to benefit information
(Abel, Neufeld, Sorel & Weeks, 2008).
Another concern about DTCPA is that it also attempts to sell life-styles to
individuals, thereby medicalizing conditions that might not be a medical problem to
begin with (Deane, 2010; Mintzes , 2002 ; Watkins, 2012). According to Barker (2008),
Direct-to-consumer pharmaceutical advertising specifically instructs patients to
ask their doctor about particular drugs to treat many previously normal, banal, or
benign “symptoms” (e.g., toenail discoloration, heartburn, diminished sexual drive
in men) and to consider them as specific medical conditions or diseases (e.g.,
dermatophytes, acid reflux disease, erectile dysfunction). (p.22)
DTCPA, in addition, conveys the message that aspects of the person’s lifestyle can
become managed using a pharmaceutical intervention (Fox & Ward, 2008; Tone &
Watkins, 2007). DTCPA imparts the message that medications can become the
alternative for healthy lifestyle choices such as a good diet or exercise (Frosch,
Krueger, Hornik, Cronholm, & Barg, 2007). Furthermore it drives consumers to seek out
certain medications they saw during the DTCPA, believing they might be beneficial to
them (Freudenheim, 2007).

DTCPA also leads to medications being overused for

conditions, which might not be safe for all consumers (Donohue, Cevasco, & Rosenthal,
2007). Women’s bodily experiences such as menstruation are often subjected to the
notion of being problematic during DTCPA (Deane, 2010; Gunson, 2007; Watkins,
2012). Since women are usually the primary caregivers of their families, DTCPA also
specifically targets this aspect of women’s lives during the advertising process (Sokol,
Wackowski & Lewis ,2010). DTCPA uses societal ideals of female beauty and sexuality
to target women more than men, by advertising medications like those that emphasize

13
anti-aging, thinness, menstrual freedom, and freedom from menopausal symptoms
(Ferguson & Parry, 1998; Mintzes, 2002; Moynihan & Cassels, 2005).
Pharmaceuticalization is defined as “the process by which social, behavioral, or
bodily conditions are treated, or deemed to be in need of treatment/intervention, with
pharmaceuticals by doctors, patients, or both” (Abraham, 2010, p.290). DTCPA is seen
as one of the methods through which pharmaceutical companies expand their markets,
promote their products and sends messages to the consumer or potential consumer
about the relationship between them and the pharmaceutical company. Sociological
literature contends that the process of pharmaceuticalization has numerous dimensions.
Pharmaceuticalization allows individuals to use medications for non-medical purposes
even among healthy people (Bell & Figert, 2012; Dew, Norris, Gabe, Chamberlain &
Hodgetts,

2014; Williams,

Martin &

Gabe, 2011). The main

concern

with

pharmaceuticalization is that the process encourages the development and advertising
of medications for conditions that are routine bodily functions, which can lead to drastic
consequences. During pharmaceuticalization, pharmaceutical companies are engaging
in the process of creating disease by allowing medications to be used more than
necessary and treating all human bodily functions as medical problems (Bell & Figert,
2012).
The process of pharmaceuticalization also puts pressure on regulatory agencies
to change or speed up the procedures that allow new drugs to be approved quickly
(Williams

et

al,

2011).

Internet

DTCPA

has

allowed

the

process

of

pharmaceuticalization to enter people’s homes today. “The home computer and Internet
have provided a window for the pharmaceutical industry into people’s domestic spaces,

14
both for information about and purchase of pharmaceuticals via burgeoning online
pharmacies” (Fox & Ward, 2008, p.856). Pharmaceutical companies use the process of
cultivating fear of diseases among people and pharmaceutical marketing to make
people anxious (Dew et al, 2014). According to Fox and Ward (2008), people’s daily
lives have now become pharmaceuticalized. Pharmaceutical companies are also
focused on developing drugs that solve issues which are due to a person’s lifestyle,
such as obesity drugs, or drugs for addictions. This allows DTCPA to become a tool that
furthers the process of pharmaceuticalization.
One of the drivers of pharmaceuticalization is medicalization (Fisher, Cottingham
& Kalbaugh, 2014). During medicalization, human bodily functions that are usually
benign or routine are seen as medical problems that require medical interventions to
manage them (Conrad, 2007). The process of pharmaceuticalization thus uses this
process of medicalization to encourage consumers to drive the process of
pharmaceuticalization (Elbe, Roemer-Mahler & Long, 2014). Moreover, when there is a
patient driven demand for drugs, this leads to consumerism. Consumerism is thought to
further drive the process of pharmaceuticalization by creating larger markets for the
drugs (Williams, Gabe & Martin, 2012). Williams et al (2011) further asserts that due to
the process of pharmaceuticalization, consumers are encouraged to see minor health
issues as serious issues, and also classify any risks as diseases, which leads to them
seeking treatment.
What Do We Know about the Advertising of OCPs?
From the years when the pill was first discovered and made available to the
general public (the 1960s) until 1980, the pill was marketed to women through their
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physicians, via medical journals (Watkins, 2012). Initially these advertisements were
mostly directed towards married women who were looking into family planning methods.
The advertisements were mainly for physicians who reinforced prescribing oral
contraception to women who were trying to avoid conception, thus reminding women of
the main role of the pill, which was pregnancy prevention at the time (Watkins, 2012).
Even though there was awareness at the time that the pill could be used to
regulate irregular periods, it was not the main reason for which the pill was marketed
then. Occasionally, unmarried women who wanted to access the pill used irregular
menstrual cycles as a reason to convince physicians of a medical reason that was noncontraceptive in nature, to be able to obtain the pill (Goldin & Katz, 2002). However the
physician’s role remained crucial in promoting the pill mostly for family planning
purposes.
When the FDA eased the restrictions of drug advertising in the 1980s,
pharmaceutical companies were able to employ enhanced advertising tactics about the
benefits of OCPs. When DTCPA became accepted in 1997, the marketing of OCPs took
a sharp turn in the 2000s (Watkins, 2012). Upon the entry of extended-cycle OCPs into
the market, the main DTCPA strategy was to show that menstruation was unnecessary
and menstrual suppression provided the perfect solution to a woman’s menstrual
problems (Gunson, 2007; Kissling, 2013). Contraceptives such as Seasonale started to
become marketed primarily for its properties to manage menstruation (Mamo & Foskett,
2009). The next section on the theory of medicalization looks at the sociological
literature on medicalization, which helps to understand how women’s bodies are treated
by the pharmaceutical and medical communities today.
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Medicalization
Sociologists define medicalization in multiple ways. Parens states, “For the last
thirty or forty years, sociologists have used the term medicalization to refer to the
process by which ‘non-medical’ (or ‘life’ or ‘human’) problems become understood and
treated as ‘medical’ problems” (Parens, 2013, p. 28). According to the work done by
sociologists, medicalization has happened to female bodies’ more than male bodies
(Lorber, 1997; Riska, 2003; Rose, 2007).

From a sociological perspective, when

conditions become medicalized, it often allows the medical and pharmaceutical industry
to produce and market drugs to individuals based on the medicalization of these
conditions. Using medications for conditions that are otherwise normal for the human
body allows society to redefine the concept of what is healthy and what is not (Conrad,
2007).
There are three steps that contribute to a condition becoming medicalized (Gabe,
Bury & Elston, 2004). The first step is to receive support from the medical and
pharmaceutical community about the issue including using medical terminology to
define the problem (Conrad & Schneider, 1980). The second step is to develop medical
intervention such as medications, thus making the problem more manageable. The third
step is to determine how physicians and patients regard the problem, which is by now
defined medically and has medical treatments to help (Conrad & Schneider, 1980).
In recent years, there has been an increase in medicalizing conditions that are
otherwise considered normal functions of the female human body (Conrad & Leiter,
2008). The medicalization of menstruation (Houppert, 1999; Fingerson, 2006), the
medicalization of pregnancy and childbirth (Brubaker & Dillaway, 2009; Oakley, 1984;
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Riessmann, 1983), and the medicalization of menopause (Dillaway, 2005) are notable
examples of women’s bodily functions becoming medicalized. Conrad (2007) argues
that pharmaceuticals have an increasing role in the process of medicalization today by
medicalizing normal processes of the human body .These conditions then become
advertised through direct-to-consumer advertising to the public (Conrad, 2007). This
strategy helps them to increase their sales of their pharmaceutical products (Conrad &
Leiter, 2004; Fox & Ward, 2008). Moreover, this process also makes medications seem
like another normal household product and reduces the understanding that medications
can have serious consequences to their consumption (Findlay, 2002).
Women’s Bodies and Medicalization
In this section, I briefly explore the literature on the medicalization of women’s
bodies. For this literature review, my focus was primarily to discuss the literature on the
medicalization of menstruation. However, I felt that it is important to demonstrate that
along with menstruation, other normal female bodily processes are also being
medicalized today. Women’s bodies experience processes that are unique and
exclusive to females, such as child birth, menstruation, and menopause. Numerous
female bodily processes are socially constructed to be pathological for the woman’s
mental and physical well-being during medicalization. Childbirth is now seen as a
normal medical event, rather than an event which the woman’s body is designed for
(Bergeron, 2007). Women are seen as patients instead of expecting mothers. Medical
interventions and medical supervision during childbirth have become the norm in
today’s society (Parry, 2008).
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Menopause is another natural process of the female body that has become
medicalized (Dillaway, 2005). The female body is seen as suffering from certain
deficiencies such as a deficiency of the hormone estrogen during this time (Kaufert &
Gilbert, 1986). Thus, the ‘hormone deficient’ female now has to accept medical help to
salvage her body, along with her mental and physical well-being (Kaufert & Gilbert,
1986). Menstruation is another process of the female body which has become so
heavily medicalized that it is now ‘treated’ with hormonal methods such as OCPs, and it
will be discussed in detail in the next section.
The Medicalization of Menstruation
Existing medical literature continues to portray menstruation as a disease or
problem for women that needs to be fixed using medical intervention such as hormonal
methods (Archer, Jensen & Johnson, 2006; Edelman, Lew, Cwiak, Nichols & Jensen,
2007; Ferrero, Abbamonte, Giordano, Alessandri, Anserini, Remorgida, & Ragni, 2006;
Sulak, Buckley & Kuehl , 2006). Some of the terms used to describe menstruation range
from ‘losing blood,’ ‘feeling unwell’ (Golub, 1983), to ‘the curse’ (Houppert, 1999). The
medicalization of menstruation has led to the disparaging of the natural female process
of menstruation by also viewing it as a hassle and problem that needs to be suppressed
or stopped (Conrad, 2007). This process now has also allowed a stigma to be attached
to menstruation, which then promotes doctors to prescribe medications to suppress
menstruation as the women continue to perceive that aspect of their life as being flawed
rather than natural (Johnston-Robledo & Chrisler, 2013). Due to the construction of
menstruation as a problematic condition by the pharmaceutical and medical community,
it is first ‘treated’ with pharmaceutical and medical interventions, using hormonal
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methods, such as OCPs. Furthermore, the advertisers of these medical and
pharmaceutical ‘treatments’ also claim that controlling menstruation has health benefits
for women (Coutinho & Segal, 1999; Kissling, 2006; Rako, 2003). Some of the
substantial health benefits from the medicalization of menstruation that are advocated
by the pharmaceutical community include reduction of the number of menstruating
days, reduction of anemia, reduction of menstrual cramps, and lack of other problems
brought about by menstruation such as mood changes (Coutinho & Segal, 1999;
Freeman, 2010; Harel, 2006; Lin & Barnhart, 2007; Panay, 2011; Shulman & Kiley,
2011).
The medicalization of menstruation comes with multiple concerns. One of the
major concerns is that menstruation is a normal part of womanhood, and therefore,
does not need any form of medical control that is also currently exerted over other
processes of the female reproductive system such as childbirth or menopause (Bobel,
2010; Dillaway, 2005; Riessmann, 1983; Stubbs & Mansfield, 2008). Another concern is
that the medicalization of menstruation allows for women’s bodies to be controlled by
medical professionals and pharmaceuticals. When the medical model dictates an issue
as problematic or pathological, medical methods are usually developed to help the
problem (Fingerson, 2006).

Bobel (2010) discards the notion that menstruation is

problematic and needs to be controlled, shortened, altered or managed by medications.
Eliminating menstruation because it is a mere inconvenience is seen by feminists as
being a perspective of the bio-medical model which labels menstruation as a hindrance
to the modern day woman’s lives rather than as a natural occurring process that women
should embrace (Kissling, 2013).
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The medicalization of menstruation and its treatment also paves way for larger
medical problems for many women. The medicalization of menstruation does not
support the assertion that menstruation is a natural occurring phenomenon which is
essential and vital to what womanhood entails for every female (Stubbs & Mansfield,
2006). Hormonal treatments such as OCPs are often prescribed for women to manage
their periods which should otherwise be reserved for women with severe menstrual
disorders such as endometriosis, thus medicalizing the normality of menstruation with
menstrual suppression as the treatment (Andrist, Hoyt, Weinstein & McGibbon, 2004).
Furthermore, the medicalization of menstruation also labels menstruation as archaic,
thus promoting pharmaceutical interventions such as OCPs to suppress menstruation
(Rako, 2003). Rako (2003) has also criticized the labeling of menstruation as archaic
and has often felt that medical professionals and pharmaceuticals, who are advocating
for the medicalizing of menstruation, are causing larger reproductive problems for
women by interfering with their natural anatomy. There are concerns that suppressing
menstruation among all women might trivialize major menstrual disorders, such as
amenorrhea that require medical intervention. When major menstrual disorders are
overlooked or left untreated due to the medicalization of natural menstruation, women
who

require

genuine

medical

treatment

could

suffer

long-term

reproductive

repercussions (Johnston-Robledo, Barnack & Wares, 2006).
There are also concerns that women might not be as informed about the risks of
the medicalization of menstruation as they should be (Society of Menstrual Cycle
Research, 2007).

Rako (2006) further states that using OCPs for managing

menstruation lacks research about long-term risks and, therefore, might lead to larger
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problems for women in the future due to changes in hormone levels. The usage of
hormonal methods for menstrual management might have already put millions of
women at risk for various health related issues such as osteoporosis due to the
fluctuation of protective hormones such as estrogen (Rako, 2006; Vanderhaeghe,
2011). Therefore, it is imperative for medical professionals and pharmaceuticals to be
particularly careful when providing women with choices to control menstruation because
it could be leading them into long term health-related issues (Society of Menstrual Cycle
Research, 2007).
Sociological Studies on the DTCPA Portrayals of OCPs
Until now, the majority of studies on the usage of the pill have been conducted in
the field of medicine. Medical literature has often labeled menstruation as a disease or
problem for women that can be managed medically with hormonal methods such as the
pill (Archer et al., 2006; Edelman et al., 2007; Ferrero et al., 2006; Sulak et al., 2006). In
this section, two major studies, conducted from within a sociological framework until
now on the DTCPA of OCPs exclusively, are discussed.
Deane (2010) analyzed television, print, and website advertisements by the
pharmaceuticals that manufacture the two OCPs: YAZ and Seasonique. Her study then
used 11 focus groups of 56 women who were students at a university in the southern
United States to understand how they felt about the DTCPA of YAZ and Seasonique.
Deane

(2010)

found

that

menstrual

management

was

encouraged

by

the

advertisements. Deane’s focus groups revealed that women preferred to draw their own
conclusions about menstruation and to make their own decisions about suppressing it,
rather than having the medical community and pharmaceuticals promoting suppression

22
to them routinely. Deane also concluded that when menstruation was constructed
through a bio-medical framework, this affected women’s feelings and understanding of
menstruation in a negative way, since women preferred to make their own decisions
about menstruation (Deane, 2010).
A study was conducted by Mamo and Foskett (2009) that analyzed the 20032004 website, print and television marketing campaigns for Seasonale, an extendedcycle OCP. One of the main findings of their study was that the definition of
menstruation was recreated during the advertising campaigns. With Seasonale’s ability
to reduce menstruation to four times a year, this reduction of menstruation was
marketed as a happier and as an attractive experience for women (Mamo & Foskett,
2009). Due to the promotion of menstrual management during the advertising
campaigns, the main function of Seasonale which is pregnancy prevention was
overshadowed by the focus on Seasonale’s ability to reduce a woman’s menstrual cycle
to four times a year (Mamo & Foskett, 2009).
Gaps in the Sociological Literature
Even though the sociological literature has the two studies mentioned above as
having conducted research exclusively on the DTCPA of OCPs, there are some
unanswered questions and gaps in the sociological literature about the topic of Internet
DTCPA of traditional of OCPs. The sociological studies done by Deane (2010) and
Mamo and Foskett (2009) show that OCPs facilitate menstrual management, thus,
medicalizing menstruation. Deane had included one traditional OCP (YAZ) in her study
and one extended-cycle OCP (Seasonique). Mamo and Foskett’s study was conducted
only on one extended-cycle OCP, Seasonale. Both their studies also looked at websites

23
of the OCPs. However, only one traditional OCP formed a part of both studies, and two
extended-cycle OCPs were included in the studies.
The literature search has demonstrated to us that numerous traditional OCPs
such as Loestrin 24Fe, YAZ and ORTHO TRI-CYCLEN LO have been on the list of the
top 200 selling drugs in the United States in recent years (Bartholow, 2011; Bartholow,
2012). This shows that traditional OCPs form an integral part of women’s health care
choices in the United States. Moreover, traditional OCPs work in a different manner on
the female body than extended-cycle OCPs. Furthermore, with the increase in Internet
DTCPA, it is beneficial to have a sociological study that looked only at pharmaceutical
websites of traditional OCPs in an in-depth manner. While we can draw on some of the
results from the studies conducted on extended-cycle OCPs, it was crucial to study
traditional OCPs exclusively in order to further our own sociological understanding on
how these traditional OCPs are represented on their own websites.
Additionally, it was also important to see how the medicalization of women’s
bodies exists through the DTCPA portrayal of traditional OCPs. We are aware that
extended-cycle OCPs like Seasonale and Seasonique are designed to reduce the
number of menstrual cycles to four times a year, and this is promoted during the
DTCPA of these contraceptives. However, we have limited sociological knowledge on if
traditional OCP websites are also promoting their products for menstrual management
and what encompasses their views on the process of menstruation. Furthermore, we
have limited understanding on how their views on the process of menstruation are
imparted through their websites, which is an influential platform for many
pharmaceutical companies today to reach out to the consumer population.
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Chapter Summary
In conclusion, we are aware from the literature review that Internet DTCPA is
becoming an important part of DTCPA and is on the rise (Charbonneau, 2010; Choi &
Lee, 2007). We are also informed that during this time that very few studies have been
conducted in the discipline of Sociology exclusively on traditional OCPs and their
Internet DTCPA. The few studies conducted in the discipline of Sociology have focused
on Seasonale and Seasonique, which are extended-cycle OCPs (Mamo & Foskett,
2009; Gunson, 2007). Deane’s study involved one traditional OCP, which was YAZ
(Deane, 2010). There is also knowledge from the literature review that women’s bodily
processes such as menstruation are often medicalized, and this can lead to the use of
OCPs to manage menstruation (Kissling, 2013; Watkins, 2012). Therefore, a study
such as this, which investigates the portrayal of traditional OCPs via Internet DTCPA, is
an asset to the existing sociological literature in several areas – specifically, Internet
DTCPA, medicalization, and women’s reproductive health. The next chapter reviews the
methodology that was used to conduct the study. It also discusses the sampling, data
collection and data analysis procedures in detail
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CHAPTER 3- METHODOLOGY
The primary aims of this study were to (1) evaluate the ways traditional OCPs are
portrayed through Internet DTCPA and (2) to examine the medicalization present on the
websites of OCPs. The data for this study came from the eight OCP websites that were
available. I used qualitative content analysis procedures to conduct this study. Content
analysis is defined as “an approach that examines written, visual, or spoken text”
(Strand & Weiss, 2005, p.161). The goal of a content analysis is for the researcher to
thoroughly examine data that is a form of communication (Flick, Kardoff & Steinke,
2004). The data can be in the form of books, websites, poetry, newspapers, letters,
Internet blogs, and any other form of document (Babbie, 2005). Photographs, pictures,
diagrams, and artistic representations can also be thoroughly examined via a content
analysis (Babbie, 2005).
While I believed that the quantitative aspect of the data is important, I was further
intrigued by being able to look at the data from a qualitative angle. In Sociology, the
researcher makes sense of situations and words by giving them meanings (Ruiz, 2009).
MacLure (2003) states that the analysis of texts involves paying close to attention to
more than just the language. Furthermore, Ruiz (2009) also states that from a
sociological perspective, data must be analyzed at the textual level and the contextual
level. This study involved a thorough examination of not just the text and its surrounding
context on the websites but also the images, videos and consumer incentives on the
websites.
A qualitative content analysis also helps the researcher look at both the manifest
and latent content of the data (Mayring, 2000). The manifest content refers to the data
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that is collected on a surface level. The latent content refers to the data has underlying
meanings that might not be easily observable to the researcher (Babbie, 2005). Babbie
(2005) states that when the text is analyzed during a content analysis, the researcher
has to also look at the reasons why the message is being communicated by text along
with what effect the textual messages are bringing to the reader. While providing
statistical accounts of the data was important and allowed me to draw certain
conclusions about the data, a qualitative content analysis allowed me to call attention to
the messages conveyed through the different categories that were examined. Looking
at the manifest and the latent content of the data also helped to make this study more
qualitative in nature.
A qualitative content analysis also assists the researcher to identify numerous
patterns and themes in the data, which then helps to obtain in-depth results from the
data (Hsieh & Shannon, 2005). Since this study looked at eight OCP websites in detail,
the qualitative content analysis helped to identify trends, differences, and patterns
between the websites. As a researcher, I additionally looked for those trends and
patterns to formulate themes that were beneficial in answering my research questions.
Sample
Even though there are numerous traditional OCPs on the market today, many of
them do not have their own websites. Therefore, to conduct this study, it was important
that the OCP had its own website that was set up by the pharmaceutical company and
was available for analysis. I obtained the list of all the OCPs in the United States that
have been approved by the FDA. Using the list, I was able to determine that eight of the

27
OCPs listed had their own websites. The table below shows the websites that were
chosen for this study:
Table 1: Websites Chosen for The Study
Name of the
Website address
pill

Date
accessed

Pharmaceutical
company

Beyaz

www.beyaz.com

November 4,
2014

Bayer

Generess Fe

www.generess.com

November 4,
2014

Allergan

Lo Loestrin
Fe

www.loloestrin.com

November 4,
2014

Allergan

Minastrin 24
Fe

www.minastrin24.com

November 4,
2014

Allergan

Natazia

www.natazia.com

November 4,
2014

Bayer

ORTHO TRICYCLEN LO

www.thepill.com

November 4,
2014

Janssen

SAFYRAL

www.safyral.com

November 4,
2014

YAZ

www.yaz-us.com

November 4,
2014

Bayer

Bayer

Traditionally, oral contraceptives are packaged with 21 hormone-containing pills,
and 7 days’ of non-hormonal pills. A menstrual cycle happens for women during the
course of her taking the 7-day pills (Association of Reproductive Health Professionals,
2008). Currently traditional OCPs are also available in 24 days of hormone-containing
pills, and 4-day non-hormonal pills (Bachmann & Kopacz, 2009). An exemption status
was received from the Wayne State University IRB to conduct this study on November
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4th 2014. The websites of the eight OCPs were saved in their entirety on November 4 th
2014, although some information was downloaded in September 2014 as well. All
website text was also printed out to ease the ability to access, preserve, and analyze
information. I began my analysis on the landing (home) page of the website and then
systematically printed out the pages that were a part of every tab. I returned later to the
website of Natazia to use and analyze the symptom checker tool again during March
2015.

There was no change in the symptom checker tool from when it was first

accessed in November 2014.
Analysis Procedures and Coding Steps
I began coding of the data with the process of open coding where I started
looking for general dimensions in the data. The next step of coding was axial coding.
Axial coding is defined as the step that helps to refine the already available concepts
from open coding (Flick et al., 2004). However, during axial coding, I also looked for
latent and manifest themes in the concepts/dimensions that become evident during
open coding. The last coding step was selective coding. Selective coding is the coding
process that helps to analyze the core categories of the study, after axial coding is done
(Flick et al., 2004). The code sheet for the study is included in the Appendix.
Data was collected and analyzed in the following categories of information on the
websites: Colors, Tabs for consumers and healthcare professionals, Slogans, Visual
imagery, Videos, Frequently asked questions, Consumer incentives, Benefits and Risks.
The presence of the medicalization of menstruation (and along with that, the simple
portrayal of menstruation) was the last feature that was studied. Coding for each of
these categories contributed fundamentally to answering my research questions. Color
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is used by pharmaceutical companies to promote their products, and other researchers
have documented that color may represent one of the most prominent marketing tools
during DTCPA (Kenagy & Stein, 2001). For this study, I reviewed the colors of the text
and the colors present on the background of the websites to obtain a thorough
understanding of how color was used on the websites. The tabs for healthcare providers
and consumers were also examined in detail. The most common types of tabs were
outlined and analyzed.
Next, I examined slogans present on the websites. Slogans are a vital part of
branding when it comes to pharmaceuticals (Ladha, 2007). According to Fransen,
Fennis and Pruyn (2007), slogans of products are very important as they try to appeal to
consumer on a personal level. They can often speak to the promotion of the person’s
wishes and desires by offering them a certain life-style or freedom, through the use of
the product advertised. Slogans also function as a source of information about the
product such as what the product can ‘cure’ or its ‘primary function’ (Ladha, 2007).
Keeping this in mind, I also looked to see if there was a cure or primary function of the
OCP promoted by slogans on the websites, and/or an offer of a certain life-style or
freedom that could come from using the OCP.
According to Kaufert and Lock (1997), pictures of women who were healthy and
beautiful were an integral part of pharmaceutical print advertising. In the past
contraceptive websites have shown independent women who are young and have
successful lives (Medley-Rath & Simonds, 2010). This led me to review all visual
images present on the websites. When images of women were present, I examined the
actions these individuals were engaging in. This was done in conjunction with observing
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whether the text surrounding the pictures correlated with sending a message about the
contraceptive being advertised. I also analyzed product imagery on the websites.
Furthermore, there was a video present on the website of Generess Fe. I assessed the
images and the language present in the video to see how this particular OCP was
portrayed in the video.
Analyzing the ‘Frequently Asked Questions’ section (when present) also provided
evidence about how the pharmaceutical company depicts the OCP on their website. I
looked to see if pharmaceutical companies used this section to repeat and reinforce
some of their main objectives from their other sections. I also investigated the portrayal
of consumer incentives (i.e., frequent buyer cards, coupons, etc.).

According to

Bhutada, Cook and Perri (2009), when consumers are exposed to coupons during
DTCPA, they tend to develop favorable attitudes towards the particular drug that is
providing them with the coupon. I wanted to see what incentives were advertised to the
consumers and healthcare providers. Therefore, I analyzed the types of incentives and
the language surrounding the incentives for each OCP.
To gain a deeper understanding on how traditional OCPS were portrayed during
Internet DTCPA, I then examined the representation of benefits and risks on the
website. The literature defines benefits as follows:
Benefits include the drug indications (what the drug treats) and level of
effectiveness, advantages over similar medications or other positive medical
claims about the advertised drug, and statements that link the drug with relief
from various symptoms including 1) testimony from an actor or other
spokesperson that his/her health care provider prescribed the drug to treat
various symptoms and 2) a suggestion to ask one’s health care provider about
the drug if suffering from these symptoms (Baird-Harris, 2009, p.7).
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Baird-Harris (2009) defines risks as, “the negative effects associated with use of the
drug, including warnings, precautions, contraindications (when to not use the drug),
adverse reactions, drug interactions, and references to situations in which one should
seek medical attention while using the drug” (p.8) . Keeping these definitions of benefits
and risks in mind, I reviewed the types of benefits and risks presented on the websites.
Previous research has also shown that during DTCPA, risks are often conveyed
differently from benefits (Kaphingst et al., 2004). Ventola (2011) also states “most DTC
ads emphasize drug benefits over risks” (p.674). Huh and Cude’s (2004) states that on
DTCPA websites home pages, benefit information was always at the top and center of
the page, when compared to risk information that was most often placed at the bottom
of the page. Based on this literature, I also examined the location of benefits and risks
on the websites along with the language surrounding both benefits and risks.
To answer my second research question on how medicalization is present on the
websites, I began by studying each website for the presence of medicalization of
menstruation. The literature review has shown that menstruation is pathologized into a
condition that requires medical treatment and intervention (Coutinho & Segal, 1999: Lin
& Barnhart, 2007; Harel, 2006; Panay, 2011; Freeman, 2010; Shulman & Kiley, 2011).
From my standpoint, menstruation was viewed as a normal process of the female body.
Therefore, any medical language showing deviance from the normal process was seen
as an example of medicalization in this study. To achieve this, I formed two main
categories that I analyzed further in detail: (1) Naming the problem; where I looked for
the evidence of the menstruation being defined as an issue, problem, symptom etc. (2)
Treating the problem; where I looked for evidence of medical treatments, particularly
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OCPs as being the answer for menstrual problems and evidence of women needing
medicine to help them with their menstrual problems. Furthermore, I examined the role
of healthcare providers on the websites and whether women were encouraged to seek
help from their healthcare providers for menstrual problems.
In order to see if menstruation was labeled as a condition that required medical
treatment/intervention, I searched for words such as “heavy”, “long”, “lasts for”, “pain”,
“cramps”, “bleeding”, “interfere”, “normal”, “loss”, “discharge”, “expulsion”, “problem”,
“symptoms”, “unpredictable”, and “unregulated” on the websites. I also explored the
context in which these words or terms were presented. The presence of the symptom
checker tool on the website of Natazia was also examined. According to Ebeling (2011),
symptom-checker tools promote and market consumers to “diagnose” themselves with
illnesses. Therefore, it was crucial for me to analyze the symptom checker tool to see
how menstruation was portrayed under the tool.
The literature review has shown that OCPs are usually given to manage
menstruation, thus medicalizing menstruation (Deane, 2010; Gunson, 2007; Mamo &
Foskett, 2009). To see if OCPs were recommended as a form of treatment, some of the
words I looked for in the data were “treat”, “help”, “relief”, “clinically proven”, “manage”,
“reduce”, “shorter”, “lighter”, “regulate” and “control”. The existence of these terms
suggests controlling and managing of menstruation thus giving me a clear indication of
how menstruation is medicalized on the websites. To deepen our understanding on the
process of medicalization on the websites, I examined the role of healthcare providers
and their ability to treat menstrual difficulties. To see the role of doctors in the process of
medicalization, I looked for terms such as “prescribe”, provide”, and “treat”. To see if
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consumers were encouraged to seek treatment with OCPs for menstrual relief, I looked
for words such as “ask”, “encourage”, “help” and “request”. The context in which these
words or terms were presented was also explored during the analysis procedure.
Chapter Summary
This chapter outlines how websites were selected for this study, along with how
the data was analyzed. Furthermore, I argue in support of using a qualitative content
analysis as the methodology to conduct this study. The next three chapters showcase
the results obtained from this study. Chapter Four presents the descriptive profiles of
the websites. Chapter Five highlights the benefits and risks presented on the OCP
websites. Chapter Six examines portrayals of menstruation and the medicalization
present on the websites.
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CHAPTER 4- DESCRIPTIVE PROFILES OF THE WEBSITES
In this chapter, I provide descriptive profiles of the websites I analyzed. The
websites of the following traditional oral contraceptive pills were analyzed in detail:
Beyaz, Generess Fe, Lo Loestrin Fe, Minastrin 24 Fe, Natazia, ORTHO TRI-CYCLEN
LO, SAFYRAL and YAZ. A qualitative content analysis of the following features on the
websites was conducted: Colors, Tabs for Consumers and Healthcare Professionals,
Slogans, Visual Imagery, Videos, Frequently Asked Questions and Consumer
Incentives.
Colors
Purple and white were the most commonly-used color schemes throughout the
websites’ layouts; specifically, four websites had a white layout and four websites had a
purple layout. Beyaz, Generess Fe, Lo Loestrin Fe and YAZ had purple layouts, while
Minastrin 24 Fe, Natazia, ORTHO TRI-CYCLEN LO and SAFYRAL were the four
websites with white layouts. Purple, white and pink were the most commonly-used color
schemes for texts across the websites. Three websites (i.e., Beyaz, Lo Loestrin Fe,
YAZ) used the purple and white color scheme for text. A purple, white and pink color
scheme for text was visible on two websites (ie, Generess Fe, ORTHO TRI-CYCLEN
LO). The table below outlines the most significant colors on each of the websites.
Table 2: Colors
Name of the pill

Background colors

Text colors

Beyaz

-Dark purple layout

-White
-Purple

Generess Fe

-Dark purple layout
-White layout

-Purple
-White
-Pink
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Lo Loestrin Fe

-Light purple layout

-Black
-Purple
-White

Minastrin 24 Fe

-White layout

-Blue
-Black
-White

Natazia

-White layout

-Blue
-Brown
-Black

ORTHO TRI-CYCLEN -White layout
LO

-Pink
-Black
-Purple
-White

SAFYRAL

-White layout

-Green
-Grey
-White

YAZ

-The entire layout starts with very light
purple at the top,
and fades to the bottom

-Purple
-White

In order to calculate how often colors were present on the website, I utilized an
online tool called “Colorfy It” (www.colorfyit.com, Retrieved: December 2015). “Colorfy
It” is a free application that allows users to enter a website address and get the color
breakdown of the website in return. The main strength of this tool is that it provides the
number of times a certain color was found on the website. According to this tool, the
most common colors on the eight websites were (with the number of occurrences in
parentheses): white (present 319 times), purple (205 times), pink (49), blue (31), brown
(16) and green (12). The individual breakdowns of website colors are as follows:
-Beyaz’s most common colors were purple (found 18 times) and white (found 15 times).
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-On the website of Generess Fe, purple was found 68 times, white was found 42 times
and pink was found 23 times.
-Lo Loestrin Fe’s website had the color purple 46 times and white 115 times.
-Minastrin24 Fe’s website had the color white present 75 times and the color blue
present 31 times.
-Natazia’s website had the color white 8 times, the color blue 13 times and the color
brown 16 times.
-The colors white was found 30 times, purple 70 times and pink 26 times on the website
of ORTHO TRI-CYCLEN LO.
-YAZ‘s website was shown to have the color purple 3 times and the color white 20
times.
-SAFYRAL’s website showed the color white 14 times and the color green 12 times.
Previous research has shown that white and purple are popular colors on
pharmaceutical websites during DTCPA, thus allowing female users to connect the
product with positive associations (Charbonneau, 2010). Greenslit (2002) states that
the colors pink and purple hold such high appeal that, in the past, pharmaceutical
companies have also packaged drugs in pink and purple to appeal to female
consumers. I also noticed that important sections of many websites usually contained
the colors white, purple and pink. The websites of Generess Fe, ORTHO TRI-CYCLEN
LO and Lo Loestrin Fe have the name of their OCPs written in purple. For slogans, a
total of five slogans were written in purple or pink out of the total seven slogans.
Generess Fe’s website and Lo Loestrin Fe’s website had one slogan each in purple.
ORTHO TRI-CYCLEN LO’s website had both their slogans in pink while Generess Fe’s
website had their second slogan in pink. Two websites had their entire text in purple.
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These were the websites of YAZ and Beyaz. The most frequent color used for tabs
were white, purple and pink. Four websites adopted this color scheme for their tabs. Lo
Loestrin Fe and ORTHO TRI-CYCLEN LO’s tabs were in the colors white and purple,
Generess Fe’s tabs were in the colors white and pink and Beyaz’s tabs were entirely in
purple. We can infer, then, that the use of white, purple and pink on these websites is
purposeful in order to appeal to the female consumer.
There were two websites where none of the common colors were used. Natazia’s
website used the colors brown and blue as its main color scheme rather than white,
purple or pink. Even though the background layout was white, the tabs were written in
blue. The only slogan was written in brown. The name of the OCP and the hormonal
dosages were also written in brown. SAFYRAL’s website consisted of the colors green
and white predominantly. Even though the background layout was white, the name of
the OCP and the only slogan was written in green. Tabs were written in white against a
green background. I observed that a photograph of the box SAFYRAL is contained in on
the website. The box was white in color and the word SAFYRAL was written in green.
The edges of the box were colored green as well. Similarly I observed the same about
Natazia’s boxed package. The name of the OCP was written in brown and the box was
predominantly colored blue. Therefore, I could see that the colors of both these
websites were the colors of the package the OCPs came in. As evident, there is
strategic and very purposeful usage of color on the eight DTCPA websites analyzed.
This is in agreement with Kenagy and Stein (2001) who state that color is one of the
most important marketing tools for pharmaceutical companies.
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Tabs for Consumers and Healthcare Providers
Website tabs were available for both potential consumers and healthcare
providers. The number of tabs available for consumers was significantly higher than the
number of tabs for healthcare providers. There were a total of 53 tabs that included
information for consumers and only 15 tabs that included information for healthcare
providers. The most number of tabs for consumers was present on the website of Lo
Loestrin Fe which consisted of a total of 21 tabs. The most number of tabs for
healthcare providers was on the website of Generess Fe which consisted of a total of
three tabs. ORTHO TRI-CYCLEN LO’s website had the second highest number of tabs
for consumers which was a total 10 tabs but had only one tab available for healthcare
providers.
The website of Beyaz had five tabs for consumers and two tabs for healthcare
providers, Lo Loestrin Fe’s website had two tabs for healthcare providers and Minastrin
24 Fe’s website had only one tab for consumers but two tabs for healthcare providers.
Natazia’s website had five tabs for consumers along with one tab for healthcare
providers. SAFYRAL AND YAZ’s websites had two tabs for consumers and two tabs for
healthcare providers per website. Below is a table listing the tabs available for both
groups.
Table 3: Tabs for Consumers and Healthcare Providers (Tab Titles)
Name of the pill
Name of tabs that include
Name of tabs that include
information for consumers information for healthcare
providers
Beyaz

-Home

-Prescribing Information

-Important Safety Information
-Sign Up

-Message to Healthcare
Professionals

-Information You Need to
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Know
-FDA Safety Communication
Generess Fe

-I am Generess

-Healthcare Professionals

-About Generess Fe

-Patient Information

-Changing to Generess Fe

-Prescribing Information

-Generess Insider
-I am Generess Program
-Understanding Birth Control
-FAQs
Lo Loestrin Fe

-Important Risk Information

-Patient Information

-About Lo Loestrin Fe
-About Lo Loestrin Fe
-Taking Lo Loestrin Fe
-Bleeding and
Spotting

-Prescribing Information

-What will my periods be
like?
-Making the switch to Lo
Loestrin Fe?
-Understanding birth control
-Understanding Birth
Control
-Contraceptive
Options
-Tools & Resources
-Tools & Resources
-Savings card
-Mobile App
-Lo Loestrin Fe education kit
-Reminders
-Body tracker tool
-Chatting with your
healthcare provider
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-Lo Loestrin Fe brochure
-Request Lo Loestrin Fe

Minastrin 24 Fe

-FAQs
-Important Safety Information

-Healthcare Professionals
-Prescribing Information

Natazia

-Natazia Can Help With
Heavy Periods

-For Healthcare Providers

-Talk To Your Doctor About
Heavy Periods
-Missed Your Pill?
-Heavy Periods? Take the
Quiz
-Safety Information
ORTHO TRI-CYCLEN
LO

-About Ortho-Tricyclen Lo
-Healthcare Professionals
-Get to know ORTHO
TRI-CYCLEN LO
-How does ORTHO TRICYCLEN LO work
-Getting Started
-What to Expect
-What if you Miss a Pill?
-Talking to Your OB/GYN
-Important Safety
Information
-FAQs

SAFYRAL

YAZ

-Full Product Information
-Information You Need To
Know

-Message to Healthcare
Professionals

-FDA Safety Communication

-Healthcare Providers

-Information You Need To
Know

-Message to Healthcare
Professional

-FDA Safety Communication

-Full Prescribing Information
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The consumer tabs can be grouped into a few main categories. The majority of
the tabs were help-providing tabs because they provided material that further informed
consumers in some way about the product under the guise of helping them. Information
present under these tabs appears to be constructed in a purposeful manner to impart
the benefits of the product to the consumers repeatedly (benefits and risks are
discussed further in the next chapter). Another category of consumer tabs were product
encouragement tabs. These tabs not only encouraged the product but also encouraged
consumers to seek medical advice when they were accessed.
Through numerous tabs, the help-providing tabs informed consumers of the
hormones in the OCPs. For example: websites of YAZ, SAFYRAL, and Beyaz had a tab
that was “Information You Need To Know”. When this tab was accessed, it brought the
consumer to “Important Facts about Bayer’s Drospirenone-containing Birth Control Pills”
which provided a summary of basic facts about the hormones used in the OCPs along
with the benefits and drawbacks of the three OCPs. The websites of Generess Fe, Lo
Loestrin Fe and ORTHO TRI-CYCLEN LO had tabs that were specific to the product
titled “About Generess Fe”, “About Lo Loestrin Fe” and “About ORTHO TRI-CYCLEN
LO”. When these tabs were accessed, consumers were informed about the hormones in
the OCPs as well as the OCPs functions. The “About Lo Loestrin Fe” tab when
accessed provides the information “Lo Loestrin® Fe is a highly effective birth control pill
with JUST 10 MICROGRAMS of daily estrogen. You get reliable contraception and
some women may experience short, lighter periods” (www.loloestrin.com). “About
Generess Fe” tab when accessed informs women “Generess Fe is a low-dose birth
control pill that gives women short, lighter, predictable periods. And, it’s highly effective
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at preventing pregnancy” (www.generess.com). This section further expands that there
“The 24 active pills contain 2 female hormones that your doctor knows and trusts: an
estrogen

called

ethinyl

estradiol

and

a

progestin

called

norethindrone”

(www.generess.com). When the “About ORTHO TRI-CYCLEN LO” tab was accessed,
the consumer was asked to “Get to know ORTHO TRI-CYCLEN LO”. Here, women are
informed, “ORTHO TRI-CYCLEN® LO contains 25 mcg of estrogen. It contains two
female hormones, an estrogen called ethinyl estradiol and a progestin called
norgestimate” (www.thepill.com).
Another type of help-providing tabs consisted of one’s providing general helpful
information about birth control. Examples of such tabs were “Understanding Birth
Control” (on the websites of Lo Loestrin Fe and Generess Fe) and “What if you Miss a
Pill?” (on the website of ORTHO TRI-CYCLEN LO and Natazia). A third category of
help-providing tabs specifically conveyed information about the menstrual benefits of
the pill. Some of these tabs can also be classified as product encouragement tabs.
There were four of these tabs present. These tabs were “Natazia Can Help With Heavy
Periods”, “Talk To Your Doctor About Heavy Periods”, “Heavy Periods? Take the Quiz”
(on the website of Natazia) and “What will my periods be like?” (on the website of Lo
Loestrin Fe). When the tab “Natazia Can Help With Heavy Periods” was accessed,
women were informed about how Natazia helps to treat heavy periods. A symptomchecker quiz to see if women experienced heavy periods was available for consumers
to take when the “Heavy Periods? Take the Quiz” tab was accessed. When “What will
my periods be like?’” tab was accessed, women were given details such as “Lo Loestrin
Fe is an ultra-low-dose birth control pill that may give you the short, lighter periods that
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you might be looking for when taking an oral contraceptive” (www.loloestrin.com) . The
fact that two websites included tabs to address menstrual management highlights
pharmaceutical companies’ efforts to advocate menstrual management benefits of the
pill. The websites of ORTHO TRI-CYCLEN LO, Lo Loestrin Fe and Generess Fe had
tabs titled “FAQs” where these sections were used to highlight all the benefits of the pill
once again to consumers.
Other product encouragement tabs seem to have been constructed by the
pharmaceutical companies for the purpose of encouraging women to seek medical
advice. A total of three tabs were present in this category. With tabs titled, “Talking to
Your OB/GYN” on the website of ORTHO TRI-CYCLEN LO, “Talk To Your Doctor about
Heavy Periods” on the website of Natazia, and “Chatting with your healthcare provider’”
on the website of Lo Loestrin Fe, consumers are guided by pharmaceutical companies
on how to talk to their physicians about their menstrual cycle and birth control needs.
Two tabs also present the consumer with information about changing or switching to
their product. For example, tabs titled, “Changing to Generess Fe” and “Making the
switch to Lo Loestrin Fe?” are designed by marketers to gather new customer bases by
convincing women to switch products. ORTHO TRI-CYCLEN LO’s website also
includes a tab called “Getting Started” that provides informational support for new users.
Similarly, tabs such as, “Get to know ORTHO TRI-CYCLEN LO”, “How ORTHO TRICYCLEN LO works?”, “Taking Lo Loestrin Fe”, and “Lo Loestrin Fe brochure” provided
informational support directly to the potential consumer.
Pharmaceutical companies ensured that healthcare providers had their own tabs
on all eight websites, so they don’t need to look through the information intended for
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consumers. The tabs for health care providers appeared to have been set up in such a
way as to make it efficient and easy for the health care provider to obtain technical
information about the product. Under these tabs, healthcare providers are also offered
samples and educational materials. Two types of tabs were commonly present for
healthcare providers – tabs for prescribing information and tabs for patient information.
While consumer tabs were accessible to anyone visiting the websites, two healthcare
provider tabs had filters to ensure that access was only gained by healthcare providers.
For Minastrin 24 Fe and Lo Loestrin Fe, the tab titled “Healthcare Professionals”
provided me with a choice of stating if I was a U.S. Healthcare professional or not. The
choice to go further was provided only for U.S. Healthcare Professionals. Therefore, I
was unable to access the healthcare provider tabs for these two websites.
Five of the websites (i.e., Beyaz, Generess Fe, Lo Loestrin Fe, YAZ, Minastrin 24
Fe) had tabs that specifically led the healthcare provider to prescribing information as
well. When these tabs were accessed, it led me to the full prescribing information. The
material in the prescribing information consisted of indications, dosages, administration
of the drug and adverse drug interactions. The material was clearly intended for
healthcare providers due to the use of clinical and medical language.

”Patient

Information” was also a popular tab and was present on the websites of Generess Fe
and Lo Loestrin Fe. When I accessed this tab on the website of Lo Loestrin Fe, I was
once again led to the prescribing information that consisted of indications, dosages,
administration of the drug and adverse drug interactions. For Generess Fe, this tab led
me to the “Highlights of prescribing information” which summarized the key points on
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indications, dosages, administration of the drug and adverse drug interactions for
healthcare providers.
One of the most interesting features for healthcare providers was the presence of
a tab that allowed the healthcare provider to access information about three OCPs
under one link. This was present on the website of SAFYRAL through a tab titled
“Healthcare Providers”. When this tab is accessed, a visitor to the website views
another table for “Women’s Healthcare Resource”, which provides access to samples
and other resources for health providers. Healthcare providers had to register (with a
login and password) in order to access this section in full. Information about three OCPs
(i.e., Beyaz, SAFYRAL, and Natazia) was provided under this one link. Physicians were
also given the option to request product samples here for all three products.
ORTHO TRI-CYCLEN LO’s website tab for “Healthcare Professionals” had a
similar structure, with sub-menus for providers underneath: “About Contraception”,
“About

ORTHO

TRI-CYCLEN

LO”,

“Counseling

Materials”,

“Important

Information”, “Full Prescribing Information”, and “Medical Information”.

Safety

All materials

needed for the healthcare providers are provided on this webpage through these six
sub-menus, which made it easier for providers to learn about and begin prescribing
ORTHO TRI-CYCLEN LO after a few short clicks.
One of the main features of the tabs for healthcare providers that were observed
is healthcare providers were directed to provide certain amount of information to
consumers. The “Women’s Healthcare Resource” section that provided information for
Beyaz, SAFYRAL and Natazia also tells healthcare providers “Bayer Savings Cards are
available to your patients. Please see www.BayerSavingsCard.com for full program
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details

and

restrictions”

(https://www.womenshealthcareresource.com/index.php,

Retrieved: January 2016). On the website of ORTHO TRI-CYCLEN LO, under the
section “Counseling Materials”, healthcare providers were informed to
Direct your patients to this site created just for them—an easy way to get
information about a range of related topics, from how oral contraceptives work to
prevent pregnancy to everything you want to know about ORTHO TRI-CYCLEN®
LO. A click gets your patient to important information about how to take the Pill,
what to do if she misses a Pill, and more (www.thepill.com)
The pharmaceutical company was encouraging healthcare providers to “direct your
patients” to look at the website that has been created exclusively for consumers.
In conclusion, even though there were more tabs for consumers than for
healthcare providers, consumer tabs functioned more to market the product (for its
benefits) than inform consumers of technical information about the product. Healthcare
provider tabs were set up to be sources of quick information about the products and
was set up exclusively for the audience that understood the language of medicine.
However, healthcare provider tabs did provide certain suggestions to the providers on
how to provide patients with a certain resource such as the OCP’s website or savings
information.
Slogans
Three of the websites in this study did not contain slogans (i.e., Beyaz, Minastrin
24 Fe and YAZ). I analyzed a total of seven slogans that were present on the remaining
five websites. In each case, it was clear that the slogans were for women (customers)
visiting the site; there were no slogans specifically for health care providers (in providerdedicated parts of the websites). Below is the table of slogans present on the websites.
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Table 4: Slogans
Name of the pill

Slogans

Beyaz

-No slogans

Generess Fe

-Little pill. Big difference
-Generess Fe is birth control with benefits

Lo Loestrin Fe

-Go Low with Lo Loestrin Fe

Minastrin 24 Fe

-No slogans

Natazia

-Natazia®, the First and Only Birth Control Pill Clinically
Proven to Help Heavy Monthly Periods

ORTHO TRI-CYCLEN LO

-Reliable Birth Control.
-Daily Assurance.

SAFYRAL

-Brought to you by Bayer, the same company that
brought you YASMIN® (drospirenone 3 mg /ethinyl
estradiol 0.03 mg)

YAZ

-No slogans

The slogans held prominent positions on the websites that allowed for
consumers to view them immediately upon entering the websites. The top left corner of
the websites was where five of the slogans were placed. They were the slogans of
SAFYRAL which was “Brought to you by Bayer, the same company that brought you
YASMIN® (drospirenone 3 mg /ethinyl estradiol 0.03 mg)” (www.safyral.com), Lo
Loestrin Fe’s slogan which was “Go Low with Lo Loestrin Fe” (www.loloestrin.com), one
of

the

slogans

of

Generess

Fe

which

was

“Little

pill.

Big

difference”

(www.generess.com) and the two slogans of ORTHO TRI-CYCLEN LO which were
“Reliable Birth Control” and “Daily Assurance” (www.thepill.com). Only two slogans
were in the middle of the page: Natazia’s slogan (“Natazia®, the First and Only Birth
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Control Pill Clinically Proven to Help Heavy Monthly Periods”) and Generess Fe’s
slogan (“Generess Fe is birth control with benefits”).
All the slogans included how the pill can help potential consumers. This finding
aligns with Ladha (2007)’s research that suggests that slogans work by giving out the
main information about the product, such as what the product can cure or its primary
function. Furthermore, the slogans emphasized functions of the pill, such as ability to
manage menstruation and ability to prevent pregnancy. Three websites had slogans
that referred directly to the pill’s birth control benefits: Generess Fe, ORTHO TRICYCLEN LO and Natazia, Generess Fe used the slogan “Generess Fe is birth control
with benefits” (www.generess.com) while ORTHO TRI-CYCLEN LO used the slogan
“Reliable Birth Control” (www.thepill.com). Natazia also stated in their slogan that their
product was the “First and Only Birth Control Pill Clinically Proven to Help Heavy
Monthly Periods”. Natazia’s slogan is immediately followed by a question at the bottom
that asks, “Do you experience heavy monthly periods?” (www.natazia.com). Natazia’s
slogan suggests that, while Natazia is a birth control, it can also be prescribed for
women to manage their heavy menstrual cycles and that this secondary benefit might
be as important as its birth control benefit. The verb “help” also implies that the pill
provides women with assistance, aid, and relief from a situation. Thus, Natazia’s slogan
suggests that heavy monthly periods are a medical problem that requires treatment
using a medicine. I discuss this idea further in a later chapter on medicalization.
Generess Fe’s slogan is “Generess Fe is birth control with benefits,” also
highlighting for women that Generess Fe has more usages than just being an oral
contraceptive pill (www.generess.com). These “benefits” are discussed in the text
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immediately under the slogan, “Generess Fe is the low-dose birth control pill that
prevents pregnancy…while helping women in need.” Specifically, it is stated that [a]
24/4 chewable, low-dose oral contraceptive, Generess Fe gives women short, lighter,
predictable

periods.

And,

it’s

highly

effective

at

preventing

pregnancy”

(www.generess.com). As with Natazia, Generess Fe’s suggestions that a “short, lighter
and predictable period” is “better” suggests that the pill can alleviate, relieve or fix
menstruation.

“Low dose” benefits were advertised on several websites, including

Generess Fe and Lo Loestrin Fe. Low dosage was conveyed directly

through the

slogan, “Go Low with Lo Loestrin Fe,” and this slogan was followed by the suggestion
that Lo Leostrin Fe is “the only birth control pill with just 10 micrograms of daily
estrogen” (www.loloestrin.com).
Overall, slogans contained direct references to birth control pills’ positive
qualities, and simultaneously used words and phrases that signified praise for the pill.
Fransen, Fennis and Pruyn (2007) state that product slogans are very important as they
are meant to appeal to individuals on a personal level. In my analysis, I observed that
advertisers may attempt to create a personal and positive connection with potential
customers through the use of slogan adjectives, for instance. In the slogan, “Little pill.
Big difference”, adjectives such as “little” to describe the pill but “big” to describe the
difference suggest the large amount of positive change women can expect in their
quality of life if they begin taking the pill (www.generess.com). The use of “reliable” in
ORTHO TRI-CYCLEN LO’s slogan, “Reliable Birth Control”, exhibits the protective and
fail-safe nature of the pill, perhaps allowing women to feel less vulnerable
(www.thepill.com). The slogan “Daily Assurance” (ORTHO TRI-CYCLEN LO) shows
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that the pill provides a woman with a consistent and regular guarantee about the
product (www.thepill.com).
Based on my analysis, slogans play an important role in DTCPA. A slogan not
only informs consumers about the primary function of the birth control pills (e.g.,
pregnancy prevention), but also makes consumers aware of other functions and
benefits of the product (e.g., menstrual management, low hormone dosages). At times
the slogans also suggest that the secondary benefits are as important as the primary
function of the pill. Additionally, slogans allow the advertiser to connect personally with
the consumer with the use of positive adjectives.
Visual Imagery
For visual imagery, the data fell into three categories. The first category was
product imagery, or evidence of how the pill (the product itself) was represented visually
on the websites. The second category was images of characters which were the
representations of people on the websites. The third category was other imagery which
consisted of any form of imagery that did not fit into the first two categories. I have also
included non-person images, such as silhouettes, in the third category.
Product Imagery
Two types of product images were present on the websites – images of the box
the pill came in and images of the actual pill pack itself. A total of 16 product images
were present on the websites. The table given below outlines the number of product
images for both consumers and healthcare providers.
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Table 5: Number of Product Images For Consumers And Healthcare Providers
Name of the pill
Total number of product
Total number of product
images for consumers
images for healthcare
providers
Beyaz
1
1
Generess Fe

1

1

Lo Loestrin Fe

1

Minastrin 24 Fe

1

Natazia

1

N/A – unable to fully
access the healthcare
providers section
N/A – unable to fully
access the healthcare
providers section
1

ORTHO TRI-CYCLEN LO

1

1

SAFYRAL

2

2

YAZ

1

1

Nine product images were present for consumers. Four of the websites (i.e.,
Generess Fe, Natazia, ORTHO TRI-CYCLEN LO and SAFYRAL) showed an actual
photograph of their pill pack to consumers. For all four websites (i.e., Generess Fe,
Natazia, ORTHO TRI-CYCLEN LO and SAFYRAL), consumers were also able to see
the actual pill tablets in their pack. However, this was not possible for the two websites
(i.e., Minastrin 24 Fe and Lo Loestrin Fe) as they only showed a diagram of the pill
pack. Only two websites (i.e., Beyaz and YAZ) lacked a picture or diagram of the pill
pack; however, the websites for Beyaz, YAZ and SAFYRAL included an image of the
boxed packaging for the product. The name of the pill was the most visible aspect on
the boxed package’s images on the website.
Product images for both consumers and healthcare providers were placed in
prominent locations on the websites. For consumers, four of the eight websites (i.e.,
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Beyaz, YAZ, SAFYRAL and Minastrin 24 Fe) placed the images related to the product
on the landing page itself. Three of the websites (i.e., SAFYRAL, Beyaz and YAZ) had
the image at eye-level as soon as the page loaded, thus increasing its visibility. The
websites for Generess Fe and Lo Loestrin Fe have a product image under the tab about
the product. Natazia’s image of their pill pack was under the tab, “Missed Your Pill?”. It
is also at the top right hand corner of the page thus making it easily visible to
consumers. For consumers, ORTHO TRI-CYCLEN LO, the product image was placed
under the tab “What If I Miss a Birth Control Pill?“ and it was in the middle right hand
corner middle of the page.
There were a total of seven product images specifically for healthcare providers.
Generess Fe’s website only provided a diagram of the pill pack for healthcare providers.
It was in the “Prescribing Information” section and fell in the middle of the prescribing
information document. However, the websites of ORTHO TRI-CYCLEN LO, YAZ,
SAFYRAL, Beyaz and Natazia placed the product image in prominent places where
healthcare providers could view them easily. ORTHO TRI-CYCLEN LO also showed an
actual photograph of their pill pack to healthcare providers. ORTHO TRI-CYCLEN LO’s
package was also placed in the top right hand corner of the page for healthcare
providers. It was beside the statement “10+ years and still going strong” and it was
placed against the background of a smiling woman (head shot only). The visual of “10+
years” imparts a message of a well-established product (www.thepill.com). This
message might also encourage healthcare providers to be more trusting of the product
due to the fact it has been around for over a decade. This is in agreement with research

53
by Kodish (2009), which states that medication advertisements today focus on letting
the audience symbolically build a trusting relationship with medications.
SAFYRAL showed a photo of the pill pack and the pill box under section for
healthcare providers. It loaded at eye-level as soon as the section for healthcare
providers was accessed. The websites of Natazia, SAFYRAL and Beyaz also showed
the pill box under the “Women’s Healthcare Resource” tab which only for healthcare
providers could access. The images were placed promptly at the top of the webpage
along with the name of the OCP, thus allowing the healthcare provider to form a visual
understanding of the product.
Pharmaceutical companies used a variety of colors to differentiate their tablets
and the product imagery illustrated this practice. Pharmaceutical companies used
brighter colors for their hormone tablets when compared to their non-hormone
(menstrual week) tablets. I was able to see pictures of the actual tablets for four of the
pill packs – Natazia, SAFYRAL ORTHO TRI-CYCLEN LO and Generess Fe. For
SAFYRAL, the pill pack was leaning against the actual box within which the product
came and was placed on the top right hand corner of the landing page. The name,
SAFYRAL, was written clearly on the pill box and it was also visible in the photo. Once
again, the tablets were clearly visible in the image. There were 21 orange tablets and
seven light orange tablets, with arrows indicating which tablet to take first (on top of the
pill pack). The prescribing information informed that the 21 orange tablets contained
hormones and the seven light orange tablets did not contain any hormones except for
folic acid (www.safyral.com). Natazia’s pill pack image was placed in the top right hand
corner of the page. The word “Start” was written on the Natazia pill pack, exactly in the
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place where the consumer should begin the first of a month of tablets. There were two
dark yellow tablets, five pink tablets, two red tablets, seventeen light yellow tablets and
two white tablets pictured in the Natazia pack. Each tablet was numbered as “1, 2, 3, . .
. 28”, which indicates the day when the tablet should be taken, along with the two white
tablets indicating the end of the pack (for days 27 and 28). Upon checking the patient
insert present on Natazia’s website about the tablets, I found the information below
which confirmed that the non-hormonal tablets were white while the hormonal pills were
in brighter colors (www.natazia.com).
2 dark yellow tablets each containing 3 mg estradiol valerate
5 medium red tablets each containing 2 mg estradiol valerate and 2 mg
dienogest
17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg
dienogest
2 dark red tablets each containing 1 mg estradiol valerate
2 white tablets (inert) (www.natazia.com)
For Generess Fe as well, the name of the product was written on the actual pill
pack’s diagram. They also had the word, “Start,” on top of the pill pack, showing in what
order the consumer should take the tablets. Here, too, it was clearly visible from the
photograph that the hormonal tablets have a different color from the tablets that do not
have any therapeutic purpose. Furthermore, they had days marked from Sunday to
Saturday to clearly indicate when the consumer should take each individual pill. Their
pills consisted of 24 green pills and four brown pills which are the iron pills. The
prescribing information states that “24 light green, round tablets (active) each containing
0.8 mg norethindrone and 0.025 mg ethinyl estradiol. 4 brown, round tablets (nonhormonal placebo) each containing 75 mg ferrous fumarate, which does not serve any
therapeutic purpose” (www.generess.com). The hormonal pills were once again of a
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brighter color than the non-hormonal pills. This is also true for ORTHO TRI-CYCLEN
LO. It says above the photo of the pill pack “The 28-pill pack contains 21 "active" pills (7
each of white, light blue and dark blue) that contain hormones that you take for 3 weeks,
followed by 1 week of “inactive” pills (green) that don't contain hormones”
(www.thepill.com). Allowing for the visualization of the actual tablets on the websites
allows for the pharmaceutical company to forge a better connection between the OCPs
and the consumers. The consumers are able to see exactly what the product looks like
through the product images that showed the actual pill packs.
Character Imagery
Five of the websites (i.e., Beyaz, Minastrin 24 Fe, SAFYRAL, YAZ and Generess
Fe) did not include any characters. ORTHO TRI-CYCLEN LO, Lo Loestrin Fe and
Natazia were the only three websites that contained images of characters. All of the
characters were women except one which was that of a male who was with a female.
There were a total of 31 images of characters on the websites. Eight images were on
the website of Lo Loestrin Fe, six images were on the website of Natazia and 17 images
were on the website of ORTHO TRI-CYCLEN LO. Seven images were repeated on the
websites with four images repeated on the website of Lo Loestrin Fe, two images
repeated on the website of Natazia and one image repeated on the website of ORTHO
TRI-CYCLEN LO. Below is a table that outlines my findings.
Table 6: Character Images
Name of
Appearance of the
the pill
person
Beyaz
-No person present
Generess
Fe

-No person present

Setting/Scenery the
person is in
-None

Action/Actions the
person is taking
-None

-None

-None
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Lo Loestrin
Fe

-A female (face not
visible)

-A water body, sky,
land

-Skydiving
-Her body is in the
shape of L as she is
descending and this
L is used to write ‘GO
LOW’

-A female (face not
visible)
Long hair flying in the
wind
Dressed in a swim suit

-A water body, sunset,
rocks

-Diving into water
-Her body is in the
shape of L as she is
descending and this
L is used to write ‘GO
LOW’

-A female (face not
visible)
-Dressed in winter
clothing with a helmet

-Snow, trees, sky

-Snowboarding
Her body is in the
shape of L as she is
descending and this
L is used to write ‘GO
LOW’

-A female (face not
visible)
-Dressed in athletic
clothing

-Rocks, water, sky,
trees

-Bungee jumping
(from a cliff with a
rope)
-Her body is in the
shape of L as she is
descending and this
L is used to write ‘GO
LOW’

Minastrin
24 Fe

-No person present

-None

-None

Natazia

-Young female’s head
shot only
-Female appears to be
of Caucasian descent
-Long hair flying in the
wind

-Sunlight, trees

-Smiling

- Young female’s head
shot only
-Female appears to be
of Caucasian descent
-Medium length hair

-Buildings, people
(appears a bit blurry)

- Making a side-ways
glance and smiling
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ORTHO
TRICYCLEN
LO

- Young female’s head
shot only
-Female appears to be
of Asian descent
-Long hair

-Sunlight, trees

-Looking directly and
appears without any
emotion

-Young female’s head
shot only
-Female appears to be
of Caucasian descent
-Long hair that is in
waves

-Chairs and table

-Smiling

-Headshots of three
women
-Appears to be
Caucasian, Asianlooking and AfricanAmerican
-Two women have long
hair. One has medium
length-hair

-Wallpaper looking
background

-Smiling

-Headshots of three
women
-All three women
appear to be of
Caucasian descent
-Two women have long
hair. One has medium
length hair.

-Wallpaper looking
background

-Smiling, laughing

- Headshot of a woman
who appears to be of
South Asian descent
-She has medium
length hair

-Sunlight, grass

-Smiling

- Headshots of two
women
-One appears to be
Caucasian and the
other appears to be
Asian
-Both have long hair

-Background is
unclear

-Smiling
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-Photograph of a male
and a female together
-Both of them appear to
be of Asian descent
-He has short hair and
she has long hair

-Background looks like
a room but is not clear

-Smiling
-Female is leaning
into the male’s chest
and he has his arm
around her

- Headshot of a female
who appears to be
Caucasian
-She appears to have
short hair or hair that is
tied to the back

-Trees

-Smiling

-Headshot of two
women who appear to
be Caucasian
-One has short hair and
another has medium
length hair

-Background is not
clear

-Smiling
-One woman has her
arm around the other
woman

- Headshot of a female
who appears to be
African-American
-Her hair appears to be
tied in the back but it
could also be short hair

-Building

-Smiling

-Headshot of a female
of who appears
Caucasian
-She has long hair

-In front of a banner
but it is unclear what is
written on the banner

-Smiling

SAFYRAL

-No person present

-None

-None

YAZ

-No person present

-None

-None

Of the 31 images, the faces of the characters were not visible for all eight images
on Lo Loestrin Fe’s website. However, the faces of the characters were visible for the
rest of the images on the websites of Natazia and ORTHO TRI-CYCLEN LO, which
made it possible to look at their racial backgrounds. For the 23 characters that were
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visible, they were of 22 young women who appeared to be in their 20s and 30s. A
young male who appeared to be in his 20s was also present in one of the images.
Caucasian-looking women were portrayed in majority of the photos. There were 13
images of Caucasian-looking women out of the total 23 images; of which the website of
Natazia had the four images and the website of ORTHO TRI-CYCLEN LO consisted of
the remaining 9 images. There were two images of Asian-looking women on the website
of Natazia, three Asian-looking women and one Asian-looking male on the website of
ORTHO TRI-CYCLEN LO. There were only two images of women who appeared to be
African-American and two images of a woman who appeared to be South Asian. Both
were on the website of ORTHO TRI-CYCLEN LO.
Even though the number of images of Caucasian-looking women was over half of
the images present on the website, both Natazia’s and ORTHO TRI-CYCLEN LO’s
websites portrayed faces of women who appeared to represent some type of racialethnic diversity as well. Jones, Mosher & Daniels (2012) show that Caucasian women
are more likely to use the pill for contraceptive purposes, compared to Asian, Hispanic,
and African-American women; therefore, pharmaceutical companies could be trying to
appeal to their largest consumer base by using more images of Caucasian-looking
women. However, the portrayal of women of color is significant because it shows that
pharmaceutical companies are recognizing other racial-ethnic groups as consumers.
The website of ORTHO TRI-CYCLEN LO had three images which contained
more than one person. Two images showed three women per image, two images were
of two women per image and one image was of a male and female together. Neither Lo
Loestrin Fe’s nor Natazia’s website contained images with more than one person. As
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mentioned earlier, some images were also repeated twice. Natazia’s website had two
images that were repeated twice. They were the images of the Caucasian-looking
female who was smiling and the Asian-looking female who was looking ahead without
any display of emotion. The website of ORTHO TRI-CYCLEN LO has repeated the
image of the woman who appears to be of South Asian descent twice. She appears to
be smiling in the photograph. The website of Lo Loestrin has repeated the images of the
woman diving into water twice, sky diving thrice and bungee jumping twice.
As stated previously, there was only one male present in all of the website
images. This was on the website of ORTHO TRI-CYCLEN LO. This image also has the
female leaning into the male counterpart while he is holding her in his arm. Her head is
resting on his chest. Both of them are smiling. This picture fell under the menu item,
‘What to Expect with ORTHO TRI-CYCLEN LO’ (www.thepill.com). This section of the
website details some of the things a woman may notice during her first three months on
the pill: “If you've just started using ORTHO TRI-CYCLEN® LO, you're probably curious
about the changes that could take place in your body. Remember that every woman's
body is different, so experiences on a new birth control pill may vary” (www.thepill.com).
It can be speculated that the male might be trying to be supportive of the female who is
probably going through bodily changes as she might have just started on the pill. His
arm around her and her leaning into him and resting her head on his chest can be
viewed as actions of support.
Through the presence of characters on the websites, the pill is also portrayed as
a product that provides women with certain life-style benefits. Themes of freedom and
happiness emerged from an analysis of the life-style benefits portrayed on these three
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websites. Images of women on the website of Lo Loestrin Fe portrayed women as
having the freedom to be adventurous while using the pill, perhaps due to being free
from contraceptive and menstrual worries. Four activities that the women were
engaging in displayed a lifestyle of adventure (e.g., skydiving, diving into water,
snowboarding and bungee jumping). A total of eight images showed female characters
that were being adventurous. On the website of Lo Loestrin Fe, the skydiving images
was presented thrice, the water diving image was presented twice, the bungee jumping
image was presented twice and the snowboarding image was presented once.
Furthermore, the text on the websites under these images reassured women that the pill
allows them to manage the burden of a regular period and enjoy freedom and
adventure. One of the sky diving images is present in the section titled, “Ready to go
low?” along with the following text:
When taken as directed, Lo Loestrin Fe is highly effective at preventing
pregnancy and can give you short, lighter periods. For Lo Loestrin Fe to be most
effective, you should take Lo Loestrin Fe exactly as directed by your healthcare
provider. Most women had a period that lasted less than 2 days per cycle on
average. Most women had periods that were lighter than normal.
(www.loloestrin.com).
Lo Loestrin Fe’s ability to manage a woman’s period was also shown in the text
surrounding two other activities: snowboarding and water diving. The text under the
snowboarding image states, “Lo Loestrin Fe is an ultra-low-dose birth control pill that
may give you the short, lighter periods that you might be looking for when taking an oral
contraceptive.” (www.loloestrin.com). Furthermore, as the women engage in these
activities, their bodies are making an L shape. Into this L shape, the words ‘Go Low’ is
written to emphasise the low level of hormones present in Lo Loestrin Fe. As discussed
in the medicalization chapter, a regular period is seen as an event of inconvenience that
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needs to be managed medically and as an issue that affects all aspects of the woman’s
well-being (Johnston-Robledo, Barnack & Wares, 2006). The medical literature has
encouraged the use of OCPs to manage menstruation, thus imparting the message that
women can lead happy and productive lives while being on the pill rather than dealing
with the pain or suffering which can accompany a regular period (Andrist, Hoyt,
Weinstein & McGibbon, 2004). When physical activities such as sky diving and bungee
jumping are shown while informing women that their period can last on an average of
two days while on Lo Loestrin Fe, pharmaceutical advertising infers that women can
plan an active life around predictable and short menstrual cycles that can be achieved
by using this birth control method.
The second theme that emerged within the analysis of life-style benefits is the
theme of happiness. There were a total of 20 background images of nature throughout
the websites. Natazia’s website had four nature images, ORTHO TRI-CYCLEN LO’s
website had three nature images and Lo Loestrin Fe’s website had 13 nature images.
The most common representations of nature were trees which were shown a total of 5
times (twice on the website of Lo Loestrin Fe, once on the website of ORTHO TRICYCLEN LO and twice on the website Natazia). The following were the other
representations of nature present on the websites : sun – four times (sunlight twice on
the website of Natazia, once on the website of ORTHO TRI-CYCLEN LO and sunset
once on the website of Lo Loestrin Fe), water and sky – three times each on the website
of Lo Loestrin, land and snow – once each time on the website of Lo Loestrin Fe, rocks
– twice on the website of Lo Loestrin Fe and grass – once on the website of ORTHO
TRI-CYCLEN LO.
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Facial expressions were visible in many of the images on the websites. There
were a total of 20 images of smiling women on the websites with 4 of them being on the
website of Natazia and 16 on the website of ORTHO TRI-CYCLEN LO. There was only
one image of a woman who was laughing and it was on the website of ORTHO TRICYCLEN LO. The image of the laughing woman was placed above the “Get to know
ORTHO TRI-CYCLEN LO” section (www.thepill.com). The woman who is laughing is
shown with two other women who are smiling. They are shown as happy, youthful and
worry-free as they are getting to “know ORTHO TRI-CYCLEN LO”. Women are
reminded in this section that ORTHO TRI-CYCLEN LO has a low level of hormones but
is very effective for pregnancy prevention and in giving them a predictable period.
Under one of the images of smiling women on Natazia’s website, the text reads,
“Natazia Is Indicated for Use by Women to Prevent Pregnancy. . . . Natazia is also
indicated for treatment of heavy menstrual bleeding in women without organic pathology
who choose to use an oral contraceptive for birth control.” (www.natazia.com). There is
also a second smiling woman portrayed under the heading, “How Well Does Natazia
Work to Help Treat Heavy Periods?” (www.natazia.com). The text continues, “When
taken as directed, prescription Natazia is highly effective at preventing pregnancy. But
that’s not all. Natazia is also highly effective at reducing heavy periods that are not
caused by any diagnosed conditions of the uterus.” (www.natazia.com). Readers of the
websites are all being reassured that help is available in the form of OCPs and, thus,
can solve their pregnancy worries along with their menstrual worries and place a smile
on their face.
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Only one image was different from the happy images presented on the websites.
On the website of Natazia, there is one image that portrays the Asian-looking woman
looking unemotional and more neutral (there was no smile or laugh in the photograph).
She was looking straight ahead as if she is trying to concentrate on something. This
woman’s image was under two menus that discussed heavy menstrual cycles as a
problem. One of the sections was “Talk to Your Doctor About Heavy Periods” and the
other section was “Heavy Periods? Take the Quiz” (www.natazia.com). These sections
of the website describe heavy monthly periods and its “symptoms,” such as soaking
through tampons and experiencing restriction of daily activities. The image of a nonsmiling woman in these sections could be conveying a message that heavy monthly
periods are a problem for women.
Other Imagery
When reviewing the websites, I also looked for any form of imagery that did not fit
into the categories of product or human imagery. Imagery in this category included the
silhouettes that were present only on the website of Generess Fe.
Table 7: Other Imagery
Name of the pill

Description of Other Imagery

Beyaz

-None

Generess Fe

-Silhouette of a walking female in a black dress, high heels,
bow, belt on her dress
-In her hand is a box that says Rx
-From the box, the following items appear: ♀, a graduation
hat, a graduation diploma, a microscope, a woman’s
business attire in an office suit, a flower shaped bow, a tea
pot set.
-Silhouette of a female sitting down, in a sleeveless
top and dark leggings with high heels
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- A magnified diagram of one pill surrounded by purple
and pink stars
-A silhouette of a female walking her dog in high heels
-Wearing black pants, a full-sleeved top, is carrying a purse,
and has a scarf on her neck
-Her dog is on a leash
Lo Loestrin Fe

-None

Minastrin 24 Fe

-None

Natazia

-None

ORTHO TRI-CYCLEN
LO

-None

SAFYRAL

-None

Generess Fe’s website showed three silhouettes of women engaging in a variety
of activities such as walking a dog, walking alone, and sitting down. These women were
surrounded by numerous items that signify female successes (and female identity is
represented by the use of the sign ♀ which is one of the items floating around the image
of the woman pictured on the website).

As mentioned earlier, Medley-Rath and

Simonds (2010) state that contraceptive advertising tends to portray women as
accomplished, successful people. It is interesting to note in every silhouette, symbolic
items are also pictured, just floating around; these floating items consist of the successrelated items - a graduation hat, a graduation diploma, a microscope, a woman’s
business attire in an office suit. The majority of the items surrounding the photographs
of women are symbolic of educational and paid work successes, such as graduation
hat/diploma and an office suit It is unclear whether the microscope is symbolic of the pill
as the culmination of science (a medical product developed through scientific research),
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the scientific accomplishments in the field of women’s health, or if it infers the success
of women in science.
Videos
Generess Fe’s website was the only website with a video. Generess Fe’s video is
titled “Watch Why We’re Different,” and the video is placed centrally on the website’s
landing page. The transcript of the video (www.generess.com) is as follows:
We all make choices, some more personal than others. Birth control is really
personal. But, what if your birth control choice could also help other women in
need? Generess Fe does just that while providing short, lighter, predictable
periods. For every prescription filled, a $5 donation is made to the participating
women’s charity of your choice. Ask your doctor for Generess Fe, the only birth
control pill that gives back. Generess Fe norethindrone and ethinyl estradiol
chewable tablets and ferrous fumarate chewable tablets are not for everyone.
You should not use Generess Fe if you are over age 35 and you smoke because
of the increased risk of having serious heart related events. Generess Fe should
not be used by woman at high risk of blood clots or those who have abnormal
uterine bleeding, certain cancers, liver disease, high blood pressure or
uncontrolled high blood cholesterol. You should not take Generess Fe earlier
than four weeks after having a baby or if you’re breastfeeding. Generess Fe will
not protect against HIV or other sexually transmitted diseases. Please visit
Generess.com to read the patient information and learn more about Generess
Fe. (www.generess.com)
The video is also important for its imagery. Silhouettes of women on the website
transform into actual women in the video. All four women shown were young and
healthy. The first woman is coming out of a pharmacy and has a bag in her hand. A
microscope and the pill pack come out of the bag, while the ♀ floats from the first
woman to the second. The second woman is enjoying a cup of a coffee in a coffee shop
when the symbol ‘♀’ lands in her palm. The video then shows a third woman running
outside and the microscope lands in her palm. The video transitions to the image of a
fourth woman who is sitting in her chair (who is then shown to open a window to a
sunny day). The video then reverts back to the first woman who is still walking with the
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bag in her hand. The first woman is in floral pattern dress with high heeled shoes. For
the second woman, only her upper body is visible as she is sitting down. She is dressed
in a shirt along with a sweater. The woman who is running is wearing appropriate
exercise clothing. The woman who is sitting in her chair looking at the sunny day is
wearing comfortable sleep wear. There are underlying themes of accomplishment and
happiness thread throughout the video. For instance, all four women in the video are
smiling, and either well-dressed professional-looking women or women engaged in
healthy activities such as running and walking.
In addition, there is theme of the importance of harnessing science for one’s own
benefit because the microscope and the pill pack come out of the bag when the woman
is leaving the pharmacy. This microscope travels to the third woman while the symbol ♀
floats to the second woman. This woman is shown again in the end walking with Rx bag
in her hand. The video is demonstrating that the women are connected through the
product Generess Fe by the movement of items such as the microscope and the symbol
♀ from woman to woman. Generess Fe therefore becomes the common link that that is
connecting the women in the positive manner portrayed throughout the video.
It is important to note that the video begins by discussing the benefits of the pill,
such as how Generess Fe offers both contraceptive and menstrual benefits. The idea
that Generess Fe can also provide a problem-free life is portrayed through happy,
smiling and active women in this video. When risks are being discussed in the video,
however, women are portrayed as continuing to smile and engage in activities, such as
having a cup of coffee and taking a walk. Images of concern are not presented
alongside concerning health information (such as, “Generess Fe should not be used by
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woman at high risk of blood clots or those who have abnormal uterine bleeding, certain
cancers, liver disease, high blood pressure or uncontrolled high blood cholesterol”)
(www.generess.com). Informing women about life-altering medical conditions while
selling the image of a smiling woman removes the seriousness of the risks and sideeffects being presented.
Frequently Asked Questions
Three websites (i.e., Generess Fe, ORTHO TRI-CYCLEN LO and Lo Loestrin
Fe) had a “Frequently Asked Questions” (FAQ) section. In my analysis I found that one
type of question was present most frequently among the FAQ sections: questions that
provided answers on how the pill works. Some of these questions were
(www.generess.com, www.loloestrin.com, www.thepill.com):
“How do I take Generess Fe?”
“When can I start taking Generess Fe?”
“How well does Lo Loestrin Fe work?”
“How do I take Lo Loestrin Fe?”
“What may be the effect of 2 days of pills with estrogen and no progestin?”
“Can taking the pill make my periods lighter and more regular?”
“Is
ORTHO
TRI-CYCLEN
LO
effective?”
(www.generess.com,
www.loloestrin.com, www.thepill.com)
Answers provided for these questions were worded so as to reaffirm the purpose and
benefits of the pill. Even when FAQ questions were about the general workings of the
pill, pharmaceutical companies took the opportunity to restate the major benefits of their
products, such as low levels of hormones, pregnancy prevention and menstrual
benefits. One of the other main points emphasized throughout answers to the FAQs is
the fact that products introduce low levels of hormones to a woman’s body (i.e., lower
than in past decades of pill use). For instance, Generess Fe’s website gives the
following answer in response to the FAQ, “What is Generess Fe?”
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Generess Fe is a low-dose birth control pill that contains 2 types of female
hormones, an estrogen called ethinyl estradiol and a progestin called
norethindrone. When taken as directed, birth control pills help to lower the
chances of becoming pregnant. They do not protect against HIV infection (AIDS)
and other sexually transmitted diseases” (www.generess.com).
The answer to “How does ORTHO TRI-CYCLEN® LO work?”, also suggests that
“ORTHO TRI-CYCLEN® LO delivers a low level of hormones to inhibit ovulation. If
ovulation does not occur, your egg is not released, and you can't get pregnant.”
(www.thepill.com). Lo Loestrin Fe’s answer to the FAQ question, “What is Lo Loestrin
Fe”, is:
Lo Loestrin Fe is a low-dose birth control pill that contains 2 types of female
hormones, an estrogen called ethinyl estradiol and a progestin called
norethindrone acetate. When taken as directed, oral contraceptives help to lower
the chances of becoming pregnant. They do not protect against HIV infection
(AIDS) and other sexually transmitted diseases.” (www.loloestrin.com).
Because of previous medical problems associated with the pill, low dosages of
hormones are seen as a benefit of some traditional OCPs in contemporary times.
Pregnancy prevention (as a benefit of the pill) is mentioned in all three FAQ
sections, almost as if to remind customers of this reason for use. Generess Fe’s website
states, “When taken as directed, birth control pills help to lower the chances of
becoming pregnant” (www.generess.com). Lo Loestrin Fe’s website declares, “When
taken as directed, oral contraceptives help to lower the chances of becoming pregnant”
(www.loloestrin.com). ORTHO TRI-CYCLEN LO’s website proposes, “If ovulation does
not occur, your egg is not released, and you can't get pregnant” (www.thepill.com). As
has been clear from previous sections of this chapter (and as I discuss further in other
findings chapters), information about menstrual management benefits is also included
among the answers to FAQs. In response to, “Is ORTHO TRI-CYCLEN® LO effective?”
and “Can taking the Pill make my periods lighter and more regular?”, the answers are
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“ORTHO TRI-CYCLEN® LO offers a highly effective, low-hormone birth control pill with
predictable periods” and “When you take ORTHO TRI-CYCLEN® LO, your periods may
be more regular and more predictable. Your periods may also become lighter and
possibly even shorter.” (www.thepill.com). For the Lo Loestrin Fe FAQ, “What may be
the effect of 2 days of pills with estrogen and no progestin?” the answer given was “A
clinical study showed that taking estrogen for 2 extra days may make a woman’s period
short and lighter than normal.” (www.loloestrin.com). The FAQ section, then, becomes
another avenue through which the benefits of the products, such as their low level of
hormones, pregnancy prevention properties and the product’s ability to manage
menstruation are conveyed to consumers.
Consumer Incentives
All of the websites studied included some form of consumer incentives. In the
table below, I outline all consumer incentives presented on the websites. I have also
included the incentives for healthcare providers in this table.
Table 8: Consumer Incentives
Name of the Consumer incentives
pill
Beyaz

-‘Get the Bayer Savings
Card’
-Savings card available
from the pharmaceutical
company for consumer
to download and print
-Patients with insurance
will pay no more than
$30 for each month’s
prescription
-Patients without

For healthcare
providers

Location of the
incentives/coupons

-Savings cards can
be printed for
patients who needs
the savings card

-At eye-level as soon
as the page loads
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insurance will receive up
to $25 off their out of
pocket expense for each
month's prescription
Generess Fe

-‘Don’t wait to talk to
your doctor. Pay no
more than $25 for your
Generess Fe
prescription with the
Actavis Patient Savings
Card!’.

-The healthcare
provider can also
provide the savings
card to the patients

-At eye-level as soon
as the page loads

-The healthcare
provider can also
provide the savings
card to the patients

-Right hand corner of
the page

-Savings card available
for immediate download
for the consumer
-Patients do not have to
pay more than $25 for a
month’s supply
Lo Loestrin
Fe

-‘Pay no more than $25
for your monthly Rx’
-Savings card available
for immediate download
for the consumer

-First tab on top

-Patients do not have to
pay more than $25 for a
month’s supply
-Phone number to call
for a card to be mailed to
you
Minastrin 24
Fe

-‘Pay no more than $25’
-Savings card available
for immediate download
for the consumer
-Patients do not have to
pay more than $25 for a
month’s supply

-At eye-level as soon
as the page loads
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Natazia

-‘Save on your monthly
prescription for Natazia’
Activate your Bayer
Savings Card now

-Savings cards can
be printed for
patients who needs
the savings card

-Not at eye-level but
below all the tabs on
the left hand side

-Patients with insurance
will pay no more than
$30 for each month’s
prescription
-Patients without
insurance will receive up
to $25 off their out of
pocket expense for each
month's prescription
ORTHO TRICYCLEN LO

-‘Join the LO-DOWN’

-Very top of the page

-Consumers can sign up
to receive information
about the product,
savings offers, and
coupons)
-Get your $15-off coupon
now! (this allows
consumers to print the
coupon if they have a
printer)
SAFYRAL

-‘Get your Bayer Savings -Savings cards can
Card’
be printed for
patients who needs
-Savings card available
the savings card
from the pharmaceutical
company for consumer
to download and print
-Patients with insurance
will pay no more than
$30 for each month’s
prescription
-Patients without
insurance will receive up
to $25 off their out of
pocket expense for each

-At eye-level as soon
as the page loads
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month's prescription
YAZ

-‘Get your Bayer Savings
Card’
-Savings card available
from the pharmaceutical
company for consumer
to download and print

-Savings cards can
be printed for
patients who needs
the savings card

-At eye-level as soon
as the page loads

-Patients with insurance
will pay no more than
$30 for each month’s
prescription
-Patients without
insurance will receive up
to $25 off their out of
pocket expense for each
month's prescription
.
Due to the placement of the incentives, consumers are able to see the incentives
as soon as they enter the websites. Consumer incentives were placed at eye-level on
five websites (i.e., YAZ, Beyaz, SAFYRAL, Minastrin 24 Fe and Generess Fe).
Incentives were placed at the top of the page for ORTHO TRI-CYCLEN LO and Lo
Loestrin Fe. Natazia was the only website where the consumer incentive was not placed
in a prominent position but, rather, at the bottom of the tabs. The specific placement of
the consumer incentives is purposeful as it makes consumers aware of the incentives
as soon as they enter the website. Six of the websites (i.e., Beyaz, Generess Fe,
Natazia, SAFYRAL, Lo Loestrin Fe and YAZ) also allowed consumers to get savings
cards from their physicians as an extra option. In all cases, consumers are able to print
coupons and/or obtain the savings card online (e.g., a link to “Get your Bayer Savings
Card”), thus accessing savings immediately. Accompanying phrases, such as “Don’t’

74
wait to talk to your doctor” (www.generess.com) and “Join the LO-DOWN”
(www.thepill.com) encourage the consumer to obtain the incentives/savings.
The text of the savings card/coupons included the monetary amount that could
be saved, such as “$25 off”, “$15 off”, “pay no more than $25” (www.loloestrin.com) and
“pay no more than $30” (http://www.savingscard.bayer.com). SAFYRAL’s, Beyaz’s,
YAZ’s and Natazia’s consumer incentives were available for both patients with and
without insurance, and the text surrounding the incentive made this clear: “[P]atients
without insurance will receive up to $25 off their out of pocket expense for each month's
prescription” while “patients with insurance will pay no more than $30 for each month’s
prescription” (http ://www.savingscard.bayer.com). Minastrin 24 Fe, Lo Loestrin Fe and
Generess Fe’s incentives informs all patients that their prescription won’t cost them
more than $25 a month as well. For example, Generess Fe’s website states “Don’t wait
to talk to your doctor. Pay no more than $25 for your Generess Fe prescription with the
Actavis Patient Savings Card!” (www.generess.com). This allows the customer to
realize that the cost of a prescription may not be prohibitive to its use. ORTHO TRICYCLEN LO was the only website that did not give a final figure on how much the
product

would

cost.

Their

website

says

“Get

$15

off

your

prescription”

(www.thepill.com). Such emphasis on cost savings on the websites is purposeful and is
meant to influence customer decisions about purchasing the product. This is in
agreement with Cline (2004) also found that financial incentives given during
prescription drug advertising can be done to motivate the consumer towards purchasing
the product.
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Chapter Summary
In this chapter, I presented descriptive findings on the following aspects of the
websites: Colors, Tabs for Consumers and Healthcare Professionals, Slogans, Visual
Imagery, Videos, Frequently Asked Questions and Consumer Incentives. This chapter
provided the characteristics of the eight websites in a detailed manner, so that readers
can understand how each website constructed information present on its pages, and
how the presentation of the information might contribute to the actual messages that
women receive when accessing the websites. Upon an analysis of the basic information
presented to women and healthcare providers on eight traditional OCP websites, it is
clear that the websites are created and managed by the pharmaceutical companies so
as to be appealing to individuals accessing the websites. The next chapter will review in
more detail the information presented on benefits and risks.
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CHAPTER 5- PORTRAYALS OF THE BENEFITS AND RISKS OF ORAL
CONTRACEPTIVE PILLS
In this chapter, I will examine how the benefits and risks of OCPs are portrayed
on the websites. I begin this chapter by listing the major benefits and risks of the OCPs
as presented on the websites. This will be followed by a discussion of the location of
both benefits and risks on the websites, and an analysis of the language surrounding
these benefits and risks.
As of early 2014, the FDA did not have any regulations on how benefits and risks
should be presented during Internet DTCPA. In June 2014, a draft was released as
guidance for online platforms (http://www.fda.gov/ downloads/ Drugs/ Guidance
ComplianceRegulatoryInformation/Guidances /UCM401087.pdf, Page 2, Retrieved:
October 2015). It states
This draft guidance is intended to describe FDA’s current thinking about how
manufacturers, packers, and distributors (firms) of prescription human and
animal drugs (drugs) and medical devices for human use (devices)that choose to
present benefit information should present both benefit and risk information
within advertising and promotional labeling (sometimes collectively referred to in
this guidance document as “promotion”) of their FDA-regulated medical products
on electronic/digital platforms that are associated with character space
limitations—specifically on the Internet and through social media or other
technological venues (Internet/social media). (FDA, 2014)
However, the main limitation of this draft is it does not provide direction as to how
products should be advertised on their own product websites. The draft further states
“Please note that this draft guidance does not address promotion via product websites”
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM401087.pdf, Page 2, Retrieved: October 2015). Therefore, the way in which
benefit and risk information is presented on the product websites such as OCP websites
continues to remain unregulated.
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Main Benefits and Risks of the Pill as Presented on the Websites
In this section, I list the major benefits and risks of OCPs presented on the
websites. Given below is a table that outlines the main benefits and risks of the OCPs
from the websites.
Table 9: Main Benefits And Risks of The Pill on The Websites
Name of the pill

Benefits listed on the
websites

Risks/side-effects on the
websites

Beyaz

-Pregnancy prevention

-Smoking risk - Women over 35
who smoke should not use the pill.
Women who smoke while on the
pill can also increase their chances
of life-threatening conditions such
as blood clots, stroke and heart
attack.

-Treat PMDD (PreMenstrual Dysphoric
Disorder)
-Presence of folate

-Other risks/side effects Increased risk of serious
conditions, including blood clots,
stroke and heart attack. Increased
risk in the first year of using the
pill. Headache/migraine, menstrual
irregularities, nausea/vomiting,
breast pain/tenderness, fatigue,
irritability, decreased libido, weight
gain, and mood changes
Generess Fe

-Pregnancy Prevention
-Low dose birth-control
-Shorter periods, lighter
periods, predictable
periods

-Smoking risk – Women over 35
who smoke to not use the pill.
Women who smoke while on the
pill can also increase their risk of
cardio-vascular side effects such
as death, blood clots, stroke and
heart attack
-Other risks/side-effects Increases the risk of serious
conditions including blood clots,
and serious heart-related events.
Nausea/vomiting,
headaches/migraine,
depression/mood complaints, pain
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with menstrual bleeding, acne,
increased weight, breast
pain/tenderness, and anxiety
Lo Loestrin Fe

-Pregnancy prevention
-Low amount of
hormones
-Shorter and lighter
periods

Minastrin 24 Fe

-Pregnancy Prevention
-Shorter and lighter
periods

-Smoking risk - Women over 35
who smoke to not use the pill.
Women who smoke while on the
pill can also increase their risk of
cardio-vascular side effects such
as death, blood clots, stroke and
heart attack
-Other risks/side-effects –
Increased risk of serious
conditions such as blood clots,
stroke and heart attack.
Nausea/vomiting, headache,
painful menstruation, weight
change, breast tenderness, acne,
abdominal pain, anxiety, and
depression
-Smoking risk - Women over 35
who smoke to not use the pill.
Women who smoke while on the
pill can also increase their risk of
cardio-vascular side effects such
as death, blood clots, stroke and
heart attack
-Other risks/side-effects –
Increased risk of serious
conditions such as blood clots,
stroke and heart attack. Headache,
vaginal infections, nausea, painful
menstruation, breast tenderness,
abnormal Pap smear, acne, mood
swings, and weight gain.

Natazia

-Pregnancy prevention
-Reduce heavy monthly
periods

-Smoking risk - Women over 35
who smoke to not use the pill.
Women who smoke while on the
pill can also increase their chances
of life-threatening conditions such
as blood clots, stroke and heart
attack
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-Other risks/side-effects Increased risk of serious
conditions such as blood clots,
stroke and heart attack.
Headache/migraine, breast
pain/discomfort/tenderness,
menstrual irregularities,
nausea/vomiting, acne, mood
changes, and weight gain
ORTHO TRICYCLEN LO

-Pregnancy Prevention
-Lighter periods, shorter
periods, predictable
periods

SAFYRAL

-Smoking risk - Women over 35
who smoke to not use the pill.
Women who smoke while on the
pill can also increase their risk of
serious cardiovascular side effects

-Low dose birth-control

-Other risks/side effects - nausea
and vomiting, headache,
nervousness, depression,
dizziness, loss of scalp hair,
appetite change, dizziness, vaginal
infections and allergic reactions

-Pregnancy prevention

-Smoking risk - Women over 35
who smoke to not use the pill.
Women who smoke while on the
pill can also increase their chances
of life-threatening conditions such
as blood clots, stroke and heart
attack

-Presence of folate

-Other risks/side effects –
Increased risk of serious
conditions, including blood clots,
stroke and heart attack.
Headache/migraine, breast
pain/tenderness/discomfort,
nausea/vomiting, mood changes
and abdominal
pain/discomfort/tenderness
YAZ

-Pregnancy Prevention
-Treat PMDD

-Smoking risk - Women over 35
who smoke to not use the pill.
Women who smoke while on the
pill can also increase their chances
of life-threatening conditions such
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as blood clots, stroke and heart
attack
-Other risks/side-effects Increased risk of serious
conditions, including blood clots,
stroke and heart attack.
Headaches, menstrual
irregularities, nausea/vomiting,
breast pain/tenderness, fatigue,
irritability, decreased libido, weight
gain, and mood changes

One of the major benefits outlined on each website is the prevention of
pregnancy. Pregnancy prevention was mentioned a total of 136 times across all eight
websites. On the website for Generess Fe, pregnancy prevention was mentioned under
all seven tabs present for a total of 36 times. The website of Natazia has a total of 21
mentions of the pill’s ability to prevent pregnancy. The information is present in all of the
tabs on the website. On the website of ORTHO TRI-CYCLEN LO, prevention of
pregnancy is mentioned 25 times, under every tab present. Pregnancy prevention is
mentioned as a benefit for a total of 41 times on the website of Lo Loestrin Fe. It is also
mentioned under all of the tabs present. For the websites of YAZ, SAFYRAL, Minastrin
24 Fe and Beyaz, pregnancy prevention is not mentioned under any particular tabs. It is
mentioned on the landing page itself. The websites of YAZ and SAFYRAL mentions
pregnancy prevention as a benefit twice, Minastrin 24 Fe mentions it as a benefit four
times and Beyaz mentions it at a benefit five times.
Another major benefit portrayed across five websites is the ability of the pill to
provide a woman with shorter, lighter and more predictable periods. Menstrual benefits
(i.e., shorter, lighter, or more predictable periods) were discussed a total of 91 times on

81
the websites studied: YAZ (once), Beyaz (once), Minastrin 24 Fe (twice), ORTHO TRICYCLEN LO (13 times of which pain management was done twice), Natazia (32 times),
Lo Loestrin Fe (22 times) and Generess Fe (22 times). Two websites had separate tabs
created to discuss menstrual benefits of the pill. Specifically, Lo Loestrin Fe had a tab
called “What will my periods be like?”, and Natazia had three tabs named, “Natazia Can
Help With Heavy Periods”, “Talk To Your Doctor About Heavy Periods”, and “Heavy
Periods? Take The Quiz”.
Being a low-dose birth control is stated as a benefit on three websites - Generess
Fe, Lo Loestrin Fe and ORTHO TRI-CYCLEN LO. Lo Loestrin Fe’s website mentions
this benefit a total of 29 times on their website. Both Generess Fe’s website and
ORTHO TRI-CYCLEN LO’s website shows this as a benefit six times. “Ultra-low-dose”
and “low-hormone” are the terms used to signify the presence of a lower amount of
hormones in the respective OCPs. Lo Loestrin Fe’s website is the most focused on this
benefit when compared to the other websites. Their slogan itself states “Go Low with Lo
Loestrin Fe,” which highlights that the OCP containing low levels of hormones is a major
part of their DTCPA. The website also has a section titled “Could going lower be right
for you?” within which it states, “Lo Loestrin® Fe is a highly effective birth control pill
with JUST 10 MICROGRAMS of daily estrogen”. In another section titled ”Ready to
make the switch to less estrogen?”, women are informed “Go low with your birth control
with Lo Loestrin Fe, an ultra-low-dose pill with JUST 10 MICROGRAMS OF DAILY
ESTROGEN. Enjoy the benefits of reliable contraception with less daily estrogen than
you get with other low-dose pills. Ask your healthcare provider about Lo Loestrin Fe and
find out if going low might be right for you” (www.loloestrin.com). Women are informed
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on the website that the OCP only contains “10 micrograms of daily estrogen”.
Furthermore, this information is written in capital letters to bring emphasis to it. Women
are assured the pill works well with such low levels of estrogen by the usage of “reliable
contraception with less daily estrogen” (www.loloestrin.com). Women are also
encouraged to take advantage of this as the website states to “find out if going low
might be right for you” (www.loloestrin.com).
The other two OCP websites did not emphasize their pill having a lower amount
of hormones as much as the website of Lo Loestrin Fe. The website of ORTHO TRICYCLEN LO also has a section titled “Low Hormone Birth Control”. The text states, “Do
you want a birth control pill that gives you a high level of effectiveness and a low level of
hormones?. . . .ORTHO TRI-CYCLEN® LO delivers a low level of hormones to inhibit
ovulation. If ovulation does not occur, your egg is not released, and you can't get
pregnant” (www.thepill.com). Here, women are being informed that the pill is highly
effective even with a low level of hormones. They are being encouraged to think about
the OCP when asked “Do you want a birth control pill?” that has not only a low level of
hormones but also has high effectiveness rates. The way in which the pill works is
shown as a benefit for women as it demonstrates how the low level of hormones
prevents pregnancy.
Generess Fe has a section called “Generess Fe, hormones you can trust”.
Furthermore, it states “Generess Fe contains a unique combination of hormones that
your doctor knows and trusts. A low-dose birth control pill” (www.generess.com). Here
women are not only being asked to trust the OCP for its low hormones, but are also
being informed that their doctor knows and trusts the OCP for the same reasons.
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Women are shown that they can have confidence in the product because it contains
“hormones you can trust” as well as “hormones that your doctor knows and trusts”. It
also states on the website “Generess Fe is a low-dose pill that’s highly effective at
preventing pregnancy” (www.generess.com). This once again demonstrates that even
though Generess Fe is a “low-dose pill”, it is able to prevent pregnancy in a “highly
effective” manner thus still fulfilling its primary function well.
The presence of folate in the OCP is listed as a benefit on two websites – five
times on the website of Beyaz and thrice on the website of SAFYRAL. The website of
SAFYRAL says “Provide a daily dose of folate supplementation, which is recommended
for women in their reproductive years. Folate lowers the risk of having rare neural tube
birth defects in a pregnancy occurring during SAFYRAL use or shortly after stopping”
(www.safyral.com). Beyaz’s website states about folate supplementation; “Provide a
daily dose of folate supplementation, which is recommended for women in their
reproductive years. Folate lowers the risk of having rare neural tube defects in a
pregnancy occurring during Beyaz use or shortly after stopping” (www.beyaz.com). In
both these examples, folate is being added as a benefit to women in the event they got
pregnant while on the OCP or “shortly after stopping”. There is no further explanation on
the websites about this folate supplementation as a benefit.
Two types of risk information existed on the websites: (1) risks for smokers who
used the OCP and (2) other risks/side effects. In the first case, website information
includes a discussion of how smokers over age 35 should not smoke while using the
pill. Some of the other risks commonly mentioned are blood clots, strokes and heart
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attacks. Other side-effects noted are headaches, nausea, weight changes and mood
changes. The table below outlines all of the risks/side-effects present on the websites.

Table 10: Risks/Side-Effects Mentioned on the Websites
Bey
az

Genere
ss Fe

Lo
Minast
Loestr rin 24
in Fe
Fe

Nataz
ia

SAFYR
AL

YA
Z

Tota
ls

12

ORTH
O TRICYCL
EN LO
20

Smoker’s
warning

2

7

16

2

2

2

63

Blood clots

4

8

51

4

35

12

7

7

128

Heart attack

8

0

51

4

28

12

4

4

120

Stroke

2

0

51

4

28

12

4

4

105

Serious heartrelated events/
Serious cardiovascular sideeffects

0

8

0

0

0

24

0

0

32

Headaches/migr
aines

1

8

19

1

7

12

1

1

50

Menstrual
irregularities
or pain
Nausea and/or
vomiting
Breast
pain/tenderness

1

8

19

1

7

0

0

1

37

1

8

19

1

7

12

1

1

50

1

8

19

1

7

0

1

1

38

Fatigue

1

0

0

0

0

0

0

1

2

Irritability

1

0

0

0

0

0

0

1

2

Weight gain or
weight change

1

8

19

1

7

0

0

1

37

Mood changes
including
anxiety and
depression

1

8

19

1

7

0

1

1

38

Appetite
changes

0

0

0

0

0

12

0

0

12
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Allergic
reactions

0

0

0

0

0

12

0

0

12

Loss of scalp
hair

0

0

0

0

0

12

0

0

12

Vaginal
infections

0

0

0

1

0

12

0

0

13

Dizziness

0

0

0

0

0

12

0

0

12

Abnormal pap
smear

0

0

0

1

0

0

0

0

1

Acne

0

8

19

1

7

0

0

0

35

Libido changes

1

0

0

0

0

0

0

1

2

Abdominal pain
or discomfort

0

0

19

0

0

0

1

0

20

In total, the websites offered 63 total mentions of smokers’ risks. On the website
of Lo Loestrin Fe, this warning was given in the middle of the website’s landing page. It
was repeated a total of 16 times throughout the different web pages on the website. The
smoker’s warning is present once at the bottom of the website for Generess Fe
accounting for a total of 7 mentions. Natazia’s warning to smokers was found at the very
top of the website amounting to a total of 12 times. For ORTHO TRI-CYCLEN LO,
warning to women who smoke appears twice on pages accessed under the “About
ORTHO TRI-CYCLEN LO” tab – in the middle and the left hand corner. It appears only
once on the web pages accessed under the remainder of the tabs on this website, for a
total of 20 mentions. The websites of Beyaz, YAZ, SAFYRAL and Minastrin 24 Fe had
the smokers warning repeated twice. Once was on the very top of the landing page and
the second time was in the middle of the landing page.
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Strokes, heart attacks and blood clots were the three most common risks of
OCPs that were mentioned on the websites. Strokes were mentioned a total of 105
times and blood clots were mentioned a total of 128 times on the websites.

As

referenced in table 10, all of the websites except Generess Fe used the terms strokes
and heart attacks to warn their consumers about this risk. The website of Generess Fe
used the term “serious heart-related events” eight times to show that as being a risk of
their OCP. ORTHO TRI-CYCLEN LO’s website also used the term “serious
cardiovascular” side-effects 24 times in conjunction with heart attacks, blood clots and
strokes on their websites. Even though blood clots and heart attacks were one of the
most common serious risks of the OCP that was mentioned on all the websites, the
number of times this information was shared varied between websites, thus
demonstrating that pharmaceutical companies are left to their own discretion during
DTCPA about how often risks should be shared . For example, Beyaz’s website and
Minastrin 24 Fe’s website mentions blood clots as a risk only four times on their website
compared to the 51 times it was mentioned on the website of Lo Loestrin Fe. Heart
attacks and strokes were only mentioned as risk four times on the website of SAFYRAL
and YAZ but they were stated as risks 51 times on the website of Lo Loestrin and 28
times on the website of Natazia. The most common side effects mentioned were
nausea/vomiting and headaches/migraines. They were mentioned a total of 50 times.
Mood changes include anxiety/depression and breast pain/tenderness was mentioned a
total of 38 times. Menstrual pain and weight gain/weight changes were mentioned 37
times. Acne was also a common side effect that was discussed a total of 35 times.
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The tabs also containing risk information were presented differently when
compared to the tabs presenting benefit information. Only two websites had tabs for
safety information that was just as noticeable as their benefits tabs. ORTHO TRICYCLEN LO’s was the only website that used the same size font for their “Important
Safety Information” tab as their benefit tabs. Minastrin 24 Fe was the only website that
had the text of the “Important Safety information” tab in a larger font than their tabs on
benefits. Except Generess Fe, all of the seven other websites had tabs that were
labeled, “Important Safety Information” or “Important Risk Information”. Natazia, Beyaz,
YAZ, SAFYRAL and Minastrin 24 Fe all placed the “Important Safety Information” tab at
the top center of the landing page. On five of the websites (i.e., Natazia, Beyaz, YAZ,
SAFYRAL and Lo Loestrin Fe), this tab was placed in the top right hand corner of the
landing page. However, on the websites of Natazia, Beyaz, YAZ, SAFYRAL and Lo
Loestrin Fe, the risk/safety information tabs were in a smaller font than the tabs that
discussed benefits. This shows that even though these tabs are at the top of the landing
page, the smaller font of these tabs could lead to them going unnoticed while
consumers are accessing the websites, thus missing pertinent risk/safety information.
Placement of Benefit and Risk Information on the Websites
This section discusses how benefit and risk information are located on the
websites. I found that benefit information held more prominent positions on the websites
than risk information. Benefit information was also available at eye-level on all of the
websites as soon as the site loaded. This is a contrast to how risk information is placed
on the websites. The table below outlines the location of the benefit and risk information
on the websites.
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Table 11: Location of Benefit And Risk Information on the Websites
Location of risk information
Name of the Location of benefit
pill
information
Beyaz

-Pregnancy Prevention - on the -Warning to women who smoke very top of the website, middle Very top of the landing page
of the website
-Treat PMDD (Pre-Menstrual
Dysphoric Disorder) - At the
top of the website, middle of
the same website

-‘Serious risks’ section and ‘Most
common side effects in clinical
trials’ section - Falls towards the
bottom of the landing page

-Presence of folate - At the top
of the website, middle of the
website
Generess
Fe

-Pregnancy Prevention - Top
and middle of the landing
page, top and middle of the
five out of the total web pages
present

-Warning to women who smoke Bottom of every webpage (however
this appears on every webpage of
this website)

-Low dose birth-control - Top
and middle of the landing
page, top and middle of the
five out of the total web pages
present

-‘Do not use Generess’ paragraph
and ‘Most common side effects’
paragraph - Bottom of the page
(however this appears on every
webpage of this website)

-Shorter periods, lighter
periods, predictable periods Top and middle of the landing
page, top and middle of the
five out of the total web pages
present
Lo Loestrin
Fe

-Pregnancy prevention - Top
and middle of the landing page
and every webpage present
-Low amount of hormones Top and middle of the landing
page and every webpage
present
-Shorter and lighter periods -

-Warning to women who smoke Middle of the landing page
(however the risks appear on every
page)
-‘Do not use Lo Loestrin Fe’
paragraph - ‘Most common side
effects’ paragraph
Bottom of the page (however the
risks appear on every page)
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Top and middle of the landing
page and every webpage
present
Minastrin 24 -Pregnancy Prevention - On
the very top of the website,
Fe
middle of the website
-Shorter and lighter periods Middle of the website

Natazia

-Warning to women who smoke Middle of the landing page
Repeated again towards bottom of
the landing page
-‘Do not use Minastrin 24 Fe’
paragraph and ‘Most common side
effects’ paragraph - Bottom of the
page

-Pregnancy prevention – Top
and middle of the landing
page, on five out of the six web
pages present

-Warning to women who smoke Very top of the landing page on
every page and once again under
Safety Information

-Reduce heavy monthly
periods - Top and middle of
the landing page, on five out of
the six web pages present

-Important Safety Information about
Natazia, including boxed warning Middle of the webpage
-‘What are the most serious risks of
taking Natazia ?’ and
What are the most common side
effects in Natazia clinical trials?’ Bottom of the page (however the
risks appear on every page

ORTHO TRI- - Prevention - Top and middle
CYCLEN LO of the landing page, top and
middle all web pages present

- Warning to women who smoke
appears twice on pages accessed
under the ‘About ORTHO TRICYCLEN LO’ tab - the middle and
-Lighter periods, shorter
the left hand corner of every page
periods, predictable periods accessed.
Top and middle of the landing
Under other tabs, this warning only
page, top and middle of all web appears once
pages present
-‘Who should not take ORTHO TRICYCLEN LO?’ and
‘What are the possible side effects
of ORTHO TRI-CYCLEN LO?’ Bottom of the page (however the
risks appear on every page)
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SAFYRAL

-Pregnancy Prevention - on the -Warning to women who smoke :
very top of the website, middle Very top of the landing page
of the website
-Middle of the page -‘Who should
-Presence of folate - At the top not take SAFYRAL or Yasmin?’ is
of the website, middle of the
written in bold font in a box
website
-‘Serious risks’ section and ‘Most
common side effects in clinical
trials’ - Falls towards the bottom of
the webpage

YAZ

-Pregnancy Prevention - on the -Warning to women who smoke :
very top of the website, middle Very top of the landing page
of the website
-Middle of the webpage - ‘Who
-Treat PMDD (Pre-Menstrual
Should Not Take Beyaz or YAZ?’ is
Dysphoric Disorder) – At the
written in bold font in a box
top of the website, middle of
the same website
-Falls towards the bottom of the
webpage -‘Serious risks’ section
and ‘Most common side effects in
clinical trials’ section

Pregnancy prevention was mentioned as benefit and function of the pill first and
at the very top on all the websites. Menstrual benefits of the pill were mentioned on all
the websites except SAFYRAL. Menstrual benefits were usually listed immediately after
the pregnancy prevention benefit or along with it. Menstrual benefits were also listed on
the top and middle of the pages on the remaining seven websites. The placement of
these benefits allowed for consumers to view this information easily as soon as they
entered the website.
The smoker’s warnings held more prominent positions on the websites compared
to the rest of risks/side-effects information. Three OCPs had the smoker’s warning in
the middle of the landing page - ORTHO TRI-CYCLEN LO, Minastrin 24 Fe, Lo Loestrin
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Fe. On the website for ORTHO TRI-CYCLEN LO, the smoker’s warning was presented
on the left hand corner of the all the pages except the landing page. The Generess Fe
website had the smoking risk placed at the bottom of the landing page. Thus, on four of
the websites, the risk warnings were placed in the middle or the very bottom of the
websites whereas information on benefits (i.e., pregnancy prevention and menstrual
benefits) was placed at the very top of the page on these websites.
Only four OCPs (YAZ, SAFYRAL, Natazia and Beyaz) placed the smoker’s
warning at the very top of their landing page. Visitors to these four websites are able to
view this warning immediately. However, it is important to note that all four of these pills
are made by the same pharmaceutical company, Bayer. In 2008, the FDA issued a
letter to Bayer informing them that their OCP, YAZ, was missing risk information of the
pill

during

Bayer’s

DTCPA

(http://www.fda.gov/downloads/Drugs/

GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLetter
sandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM143477.pdf,

Retrieved:

October 2015). Such warnings by the FDA could be the reason why YAZ, SAFYRAL,
Natazia and Beyaz have the smoker’s warning at the very top of their website landing
pages. Still, the presentation of these warnings on the websites of Natazia and
SAFYRAL are different than the presentation of benefits in that risk information appears
in a smaller font when compared to benefit information. Furthermore, even though
Natazia, Beyaz, YAZ and SAFYRAL had an “Important Safety Information” tab placed at
the top center of the landing page, these tabs were in a much smaller font than the tabs
that discussed the benefits of these OCPs.
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I also examined the placement of information about other side-effects/risks. On
all eight websites analyzed, information on other risks/side-effects was found only if one
scrolled down, at the bottom of the websites. This was in stark contrast to the benefit
information that was always at the top of the websites. The placement of side-effects at
the bottom of the website pages may work to prevent a consumer from viewing this
information easily as they access the websites. In the event that women do not scroll
down to the bottom of the websites, they could overlook this information entirely. It could
be argued that this is a very purposeful minimization of the side-effects of the pill.
Hicks, Wogalter and Vigilante (2005) state that finding risk information on drug
websites usually requires mouse clicks and/or scrolls, while accessing information on
drug benefits does not require this extra physical activity, because benefit information is
present as soon as the website loads. Based on the results of Hicks et al.’s (2005)
findings, I explored further to see if mouse clicks and/or scrolls were required to access
information on most common side effects. I excluded the “Smoking Warning” in this
analysis, as the placement of the smoking warning on the websites was more visible
than information on other risks/side-effects. The table below shows the number of
scrolls and/or clicks that were required to access other risks/side-effects information on
the websites.
Table 12: Number of Scrolls and
Risks/Side-Effects Information
Name of
Benefits
OCP
Beyaz
-None, information
loads as soon as page
loads
Generess Fe

Clicks Required to Access Benefit and
Risks/Side-Effects
-Have to scroll down on landing page for
side-effects/risk information

-None, information
-Have to scroll down on every page for
loads as soon as page side-effects/risk information
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loads

-Number of mouse clicks: One click to enter
tab ‘About Generess Fe’. Scroll down
required to reach ‘What about side effects?’

Lo Loestrin
Fe

-None, information
-Have to scroll down on every page for
loads as soon as page side-effects/risk information
loads
-Number of mouse click: One click on link
‘Important Safety Information’

Minastrin 24
Fe

-None, information
-Have to scroll down on landing page for
loads as soon as page side-effects/risk information
loads
-Number of mouse clicks: One click on link
‘Important Safety Information’

Natazia

-None, information
-Have to scroll down on every page for
loads as soon as page side-effects/risk information
loads
-Number of mouse clicks : One click on link
‘Safety information’

ORTHO TRICYCLEN LO

-None, information
-Have to scroll down on every page for
loads as soon as page side-effects/risk information
loads
-Number of mouse clicks : One click on link
‘Safety information’

SAFYRAL

-None, information
-Have to scroll down on landing page for
loads as soon as page side-effects/risk information
loads

YAZ

-None, information
-Have to scroll down on landing page for
loads as soon as page side-effects/risk information
loads

All the websites required the user to scroll down for information on other risks
and side effects. For the websites of ORTHO TRI-CYCLEN LO, Natazia, Minastrin 24
Fe, Lo Loestrin Fe and Generess Fe, one mouse click also allows for access to
risks/side effects information. On the contrary, benefit information was visible as soon
as all the websites loaded, thus not requiring one to scroll down or click to access this
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information. It can be argued that when consumers have to scroll through the websites
or click to access risk information, they could potentially overlook the presence of this
information. Therefore, quicker accessibility to all forms of risks/side-effects information
would be beneficial to consumers who are accessing the websites. Furthermore, it
would be advantageous for consumers if the risk information is placed in the same
prominent locations as the benefit information.
Language Surrounding the Presentation of Benefits and Risks on the Websites
While analyzing the portrayal of benefits and risks on OCP websites, the
language surrounding the benefits and risks on the websites were also analyzed in
detail. I found that statistics were provided when benefits were discussed, but these
statistics were noticeably absent in any discussion of risks or side-effects.

When

pregnancy prevention was portrayed as a benefit of the pill, terms like “highly effective”
and “99% effective” were provided to show evidence of effectiveness.

Pregnancy

prevention is also discussed in a more clinical or scientific term on the websites. For
example, on the websites for SAFYRAL, Beyaz, YAZ, and Minastrin 24 Fe, phrases
such as “approved to prevent pregnancy”, “prescription birth control”, “99% effective”
and “5% failure rates” provide a loose link to scientific evidence and medical approval.
These phrases also hint that consumers should assume the truthfulness of this
information. When menstrual benefits are discussed, very specific numerical data was
provided to lend credibility to the information on the websites and to indicate exactly
how beneficial the OCPs might be in altering women’s cycles. For instance, Generess
Fe’s website declares that its usage leads to, “… predictable periods, starting for most
women on Day 27” (www.generess.com), and Minastrin 24’s website suggested that its
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usage

leads

to

periods

“…

averaging

fewer

than

3

days,

by

Cycle

6”

(www.minastrin24.com).
When side-effects of the pill were discussed, detailed statistics were not
provided. Even when serious risks such as heart attacks, strokes and blood clots are
mentioned, there is no evidence provided directly from the clinical studies to show how
many women or what percentage of OCP users have suffered from these risks/sideeffects. On the website of Natazia, there is a detailed discussion about the studies that
have examined Natazia’s ability to treat heavy menstrual bleeding. However, the side
effects from the same clinical study are mentioned at the very bottom of the website
without detailed data or statistics. Below is the text discussing the results of the study
(www.natazia.com).
Results in women with heavy periods
Most women in the two studies described above suffered from heavy bleeding
specifically (85%). For these women with heavy periods who took Natazia,
menstrual bleeding was reduced over 90 days by an average of 72% in one
study and 78% in the other. In comparison, women who took a placebo saw an
average of 14% and 32% bleeding reduction in the two studies (see chart).
(www.natazia.com)
Directly below the results, the most common side effects from the same clinical
trial data were provided: “What are the most common side effects in Natazia clinical
trials?

The

most

common

side

effects

were

headache/migraine,

breast

pain/discomfort/tenderness, menstrual irregularities, nausea/vomiting, acne, mood
changes, and weight gain” (www.natazia.com). The content of the text clearly shows
how the beneficial results of a clinical trial are given more importance compared to
results about risks or side effects.
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Additionally, I found evidence of contradictory language when information on side
effects is presented. For instance, the website of ORTHO TRI-CYCLEN LO states:
“ORTHO TRI-CYCLEN® LO has a low occurrence of common side effects. All oral
contraceptives are associated with serious side effects” (www.thepill.com). These
sentences are written back to back on the website. It is noticeable that while the
company is stating their product has a low occurrence of side effects, they are
simultaneously emphasizing that all OCPs have serious side effects. There are no
clinical studies or statistics cited to compare the occurrence of common side effects
between other OCPs and ORTHO TRI-CYCLEN LO, and the absence of numbers
allows this DTCPA information to be taken at face value by consumers who has to
unknowingly accept the benefits without knowing full information on risks.
The website of Generess Fe declares that, “In clinical studies, weight gain,
decrease in sexual desire, and mood swings occurred at low rates for women taking
Generess Fe1” (www.generess.com). Even though the side effects are mentioned and
proclaimed as uncommon among users, there is no further explanation or justification of
these statements. Furthermore, the superscript number 1 at the end of this statement
only led to the prescribing information of Generess Fe and not to any more evidence of
the “low rates” of the side effects. A superscript number was also found on a statement
about Lo Loestrin Fe’s side effects, after this statement: “It is preferred that women
taking birth control pills choose a pill with lower doses of estrogen. This is because lowdose birth control pills are just as effective and have fewer side effects 3”
(www.loloestrin.com). However, here I found no immediate link to the source of the
information in the statement, yet there was a link to an article that stated the “LoLo Fact”
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that, in a recent survey of a 1000 current/potential consumers of the birth control pill, it
was found that “93% are interested in a pill with the lowest amount of daily estrogen and
78% worry about the amount of hormones they are exposed to through the use of pills”
(www.loloestrin.com). Once again, the benefit information was readily available for
women, with statistics provided, whereas the risk information did not come with
equivalent numerical justification.
Some of the information on risks or problems with OCPs also blamed the
individual consumer or patient. For instance, even though pregnancy prevention is
lauded as a benefit of the pill on all eight websites, not taking the pill correctly and
getting pregnant is shown as a failure of the consumer and not the failure of the
pharmaceutical product. Generess Fe’s website states, “Your chance of getting
pregnant depends on how well you follow the directions of taking your birth control pills”
(www.generess.com). The website of Natazia further suggests, “In order to be sure
your birth control pill is going to be most effective, it’s important to remember to take
your pill every day, as directed. The power is in your hands. If you miss one or more
pills, you could get pregnant” (www.natazia.com). In both cases, DTCPA includes a
warning to the customer about proper use, almost presenting this information as a
possible risk if women opt to use the OCP.
Chapter Summary
In this chapter I examined the information on OCP benefits and risks, as
presented by the eight websites I studied. This chapter was divided into three main
sections: major benefits and risks of OCPs on the websites, location of benefit and risk
information on the websites, and language surrounding the presentation of benefits and
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risks on the websites.

Pregnancy prevention and an altered menstrual cycle were

presented as the main benefits of OCPs. Pregnancy prevention was mentioned a total
of 136 times across the websites and an altered menstrual cycle was shown as a
benefit 91 times across the websites. The pill containing a low dose of hormones was
shown as a benefit of a total of 41 times on three websites (Lo Loestrin Fe, Generess
Fe and ORTHO TRI-CYCLEN LO). Having folate in the OCP was listed as a benefit a
total of eight times on the websites of Beyaz and SAFYRAL.

Therefore, the total

number of times benefits were mentioned was 265 times. Two types of risks were found
on the websites: Smokers’ warnings and other risks/side-effects. The smoker’s
warnings were mentioned a total of 63 times on the websites. Strokes, heart attacks and
blood clots were presented as the three other most serious risks of the OCPs. Strokes
were mentioned a total of 105 times and blood clots were mentioned a total of 128 times
on the websites. Heart-attacks and/or serious cardio-vascular events were mentioned a
total of 144 times on the websites.
Benefit information such as pregnancy prevention and menstrual benefits was
presented at eye level on all of the websites. Menstrual benefits were directly
underneath or with the information on pregnancy prevention. The warning to smokers
was available on all websites and its placement was much more prominent than the
placement of information on other risks/side-effects. Four OCPs (YAZ, SAFYRAL,
Natazia and Beyaz) placed the smoker’s warning at the very top of their landing page.
Three OCPs (ORTHO TRI-CYCLEN LO, Minastrin 24 Fe, Lo Loestrin Fe) had the
smoker’s warning in the middle of the landing page. On the website for ORTHO TRICYCLEN LO, the smoker’s warning was also presented on the left hand corner of the all
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the pages except the landing page. The Generess Fe website had the smoking risk
placed at the bottom of the landing page. When other risks/side-effects information was
presented, they were always placed at the bottom of the websites. Upon looking to see
how many scroll downs or mouse clicks it took to access this information, I determined
that all of the websites required the user to scroll down for information on other risks/
side effects. On the websites of ORTHO TRI-CYCLEN LO, Natazia, Minastrin 24 Fe, Lo
Loestrin Fe and Generess Fe, one mouse click also allowed to access the information
on other risks/side effects.
When I compared the language surrounding benefits and risks, I established that
benefits were presented in more convincing language than the risks. Pregnancy
prevention was portrayed as a benefit of the pill with terms like “highly effective” and
“99% effective” given as evidence of effectiveness of the OCP. Furthermore, when
menstrual benefits are discussed, “average of two days”, “menstrual bleeding was
reduced over 90 days by an average of 72% in one study” and “lasting under 3 days”
are given as proof to show the OCP can help alter menstruation. Statistical language
and clear data was absent when risks and side-effects were being mentioned. When
side effects were mentioned, terms such as “fewer side effects” and “low occurrence of
common side effects” were used to indicate the product had lesser side effects.
However, there were no statistics given on how many women experienced these side
effects while using the OCP. Up to this point, I have analyzed the benefits and risks of
the OCPs as portrayed on their websites. The next chapter presents data on the
medicalization of menstruation, as presented on the websites.
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CHAPTER 6 - MEDICALIZATION OF MENSTRUATION ON WEBSITES
FOR ORAL CONTRACEPTIVE PILLS
Conrad

(1992) states that “Medicalization consists of defining a problem in

medical terms, using medical language to describe a problem, adopting a medical
framework to understand a problem, or using a medical intervention to “treat” it” (p.
211). This chapter has been divided into two major sections based on Conrad’s
definition of medicalization. The first section discusses the symptoms of menstruation
and looks into how menstruation is seen as a problem in medical terms. The second
section looks at how the symptoms of menstruation are treated using OCPs. This
section also examines the role of healthcare providers in facilitating the treatment of
these menstrual symptoms using OCPs.
Naming the Problem
While I analyzed the websites for OCPs and, therefore, contraceptive benefits of
the pills should be primary, a major theme in my analysis is the medicalization of
menstruation. Menstrual management was heralded as a major secondary benefit of
OCPs on all websites, and medicalization of menstruation represented a significant
aspect of the website’s discussion of this secondary benefit. The websites I analyzed
used three hallmark symptoms to define menstruation as a medical problem for women:
heaviness of bleeding, length of bleeding, and unpredictability. Defining menstruation
through negative symptoms also allows for websites to argue for intervention and
treatment and OCP use is portrayed as the way to achieve a better menstruation. Thus,
defining menstruation in negative terms (through symptoms) and then highlighting the
need for treatment and intervention are the first steps in the process of the
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medicalization of menstruation on these websites. In the paragraphs that follow, I focus
on the data collected from the study to illustrate this finding.
Heaviness as a Symptom
Heaviness of the menstrual flow was shown as a problem associated with
menstruation. Generess Fe’s website states, “… intensity of their periods

...”

(www.generess.com). The usage of “intensity of their periods” depicts a form of
suffering during menstruation that is hard to bear or intense for the woman. This also
helps the pharmaceutical company to set the stage to help women deal with this
“intensity”.

Reduction of this “intensity” to alleviate suffering during menstruation

becomes the solution for the pharmaceutical company.
Natazia’s website focused the most on the heaviness of menstrual flow being a
problem with the word ‘heavy’ used 37 times on the website of Natazia as a symptom of
menstruation. Natazia’s website asks, “Have you ever wondered whether your heavy
periods are “normal”—and whether there’s anything you can do about them?”
(www.natazia.com). There is no definition of what a “normal” period is or how long it
might last; yet women are given the impression that a “heavy” period might not be
“normal”. Even though the website of Natazia does not give an explanation of what a
“normal” period is, the majority of the discussion on the website is focused on “heavy
periods”. For instance, the questions given below are asked on the website to see if the
woman is experiencing heavy periods:
Do you regularly soak through pads or tampons, and sometimes wake up in the
middle of the night to change them? Are you afraid of having bleeding accidents
in public? Are you concerned about how frequently you have to change pads or
tampons during your cycle? Do you sometimes miss work or stay in at night
because of your heavy bleeding? (www.natazia.com)
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The most visible aspect of medicalization here is how menstruation is portrayed
through a symptomatic lens. Women are being asked if they are suffering from the socalled symptoms of heavy menstruation, such as soaking through pads or tampons,
waking up in the middle of the night to change them, high frequency of changing pads
or tampons, worries about having bleeding accidents in public, or missing working or
staying home due to heavy bleeding. These symptoms are not only physical but also
are often based on perceptions of how problematic periods are for a woman’s daily life.
Asking women if they “miss work or stay in at night because of your heavy bleeding?”
sends the message that the problem of heavy bleeding transcends into all aspects of
the woman’s life, and affects the quality of her work and social life (www.natazia.com).
Because perception and subjectivity is built into these questions, it allows individual
women to feel as if their periods might be “heavy” without knowing whether that is the
case, encouraging them to define their own situation as problematic and potentially
worse than “normal.” The website of Natazia goes a step further to inform women with
this information: “If your bleeding is heavier than normal, it’s good to know that help is
available. It doesn’t matter whether you’ve been dealing with heavy periods for months
or even years. And it doesn’t matter whether someone else you know seems to have
heavier periods and seems to manage just fine” (www.natazia.com). Here, women are
encouraged to use medical intervention for their “heavy bleeding”. Natazia furthers this
with a symptom checker quiz, which will be discussed later in this chapter.
Length of Flow as a Symptom
Apart from heavy periods, length of flow is also shown to be a potential symptom
of “abnormal” and untreated menstruation. Minastrin 24 Fe’s website suggests that
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menstruation may be worth treating medically by stating “if it is unusually heavy or lasts
for more than a few days” (www.minastrin24.com). However, there is no clarity as to
what constitutes “unusually heavy” or “more than a few days”. Women are left to guess
whether their periods are longer than “normal” and therefore worthy of treatment.
Importantly, though, the question of normality is planted in the minds of visitors to the
website. However, a period that is “unusually heavy” or “more than a few days” is
portrayed as a problem from a medical angle. This allows for establishing a way in
which a period that is “unusually heavy” or “more than a few days” to become a
treatable issue.
Untreated menstruation is defined as negative and abnormal on the websites of
Lo Loestrin Fe and Generess Fe too. Generess Fe’s website asserts that “Women also
reported their periods to be lighter than normal” (www.generess.com). A similar
statement was also mentioned on the website of Lo Loestrin Fe. It describes that “Most
women had periods that were lighter than normal” (www.loloestrin.com). The term “than
normal” was used nine times on the website of Lo Loestrin Fe and twice on the website
of Generess Fe. Looking at the context, the term “than normal” is provided as a
comparison of how regular menstruation is versus how the new menstrual cycle will be
for women who are on the OCP. The term ‘normal’ therefore paints menstruation
negatively and anything different from “than normal” is now considered better. The
question of normality of one’s menstruation is planted in the through the inference of
“than normal” being considered better. However to achieve a menstruation that is
different “than normal”, women have to use a form of medical intervention which is the
OCP.
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Other Symptoms
Lack of predictability was also defined as a symptom of menstruation on the
websites. The website of ORTHO TRI-CYCLEN LO describes a problematic period as
one that that consists of “periods have been bouncing all over the calendar”
(www.thepill.com). The usage of the phrase “bouncing all over the calendar” to describe
menstruation hints that any large variations in the arrival of menstruation is inconvenient
and perhaps challenging (www.thepill.com). Pain is also shown as a symptom of
menstruation on the ORTHO TRI-CYCLEN LO website twice (www.thepill.com). The
website states women experience “pain or other symptoms during menstruation”. The
website also uses the term “menstrual cramps” to denote painful menstruation
(www.thepill.com). Menstruation is medicalized here with the usage of the word
“symptoms”. However, once again there is no clarification as to what “other symptoms”
constitute of. Women are left to assume that menstruation is accompanied by “pain or
other symptoms”. This frames menstruation through a very medical lens where the
pharmaceutical company is showing women that menstruation is accompanied by
“symptoms”, thus establishing a need to treat or alleviate these “symptoms”.
Only three websites mention Pre-Menstrual Syndrome (PMS) on their websites:
YAZ, Beyaz and ORTHO TRI-CYCLEN LO. Even on these three websites, there is a
curiously limited and vague discussion of PMS, however. PMS is defined as “a less
serious set of symptoms occurring before your period” on the websites of both YAZ and
Beyaz (www.beyaz.com; www.yaz-us.com). However, there is no further explanation of
what the “less serious set of symptoms” are. Immediately after this information, YAZ
and Beyaz’s websites state that their products are “not approved to treat PMS”. The
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website of ORTHO TRI-CYCLEN LO states that bloating “is part of what healthcare
professionals call premenstrual syndrome. The good news: bloating is often temporary
and relieved by the arrival of menstruation” (www.thepill.com). Thus, all three websites
that mention PMS are very careful to note that OCPs cannot be used to treat this
syndrome. The focus of discussions of menstrual management is on managing the daily
experience of menstruation, rather than conditions or syndromes sometimes associated
with it. The literature shows that the medical and pharmaceutical community has been
trying to medicalize PMS for almost two decades. According to Figert (1996), in 1986,
PMS was added under the name Late Luteal Phase Dysphoric Disorder (LLPDD) in the
appendix of the Diagnostic and Statistical Manual of Mental Disorders (DSM-3) as a
mental condition. Even though there was strong opposition of placing a condition that
only affected women into a psychiatric document, the medical and pharmaceutical
community at the time strongly backed this decision. Placing LLPDD into the appendix
was seen as a compromise from the medical community to the protest faced about
labeling PMS as a medical issue (Knaapen & Weisz, 2008). “LLPDD/PMDD and its
placement in the appendix can be plausibly seen as a tentative first step toward creating
a new formally recognized psychiatric diagnostic category” (Knaapen & Weisz, 2008,
p.127). Even now, as evident on the websites, women are being informed by these
websites that PMS is “set of symptoms” (www.beyaz.com; www.yaz-us.com). So, there
is no evidence that PMS is demedicalized due to the lack of in-depth discussion on the
websites. The next section focuses on how the symptoms and problems caused by
menstruation are reduced and treated using OCPs.
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Treating the Problem
Treating the problem using medical intervention is an important aspect of
medicalization (Conrad, 1992). Thus, establishing treatment for problematic health
experiences (here, menstruation) is an essential step in the process of medicalization.
In this section, I also examine the role of healthcare providers as the facilitators of
medicalization, as portrayed on the eight websites I analyzed. During medicalization,
healthcare providers continue to be in the frontlines as the experts in providing medical
treatments (Conrad, 2005). During my analysis, I too found that the main role doctors
held was that of the expert who could provide the consumer with medical direction and
treatment. The websites encouraged women to ask their healthcare providers about
their symptoms as well as the functions of the OCPs (and thus, the treatment). Women
were encouraged to consult their healthcare providers a total of 13 times on the
following websites:

Lo Loestrin Fe (four times), Natazia (five times), Generess Fe

(twice) and ORTHO TRI-CYCLEN LO (twice). Beyaz, YAZ, Minastrin 24 Fe and
SAFYRAL’s websites did not contain direct information that encouraged women to talk
to their doctors. The use of “ask your doctor”, “ask your healthcare provider,” and “set
up an appointment with your gynecologist or healthcare professional” are examples of
the instructions women received to obtain expertise from providers, along the way to
receiving

the

OCP

as

treatment

(www.loloestrin.com,

www.thepill.com,

www.natazia.com) .
The discussion of how OCPs alter and provide women with menstrual relief is set
up in such a way that consumers are made aware of the importance of
treatment/symptom relief. In other words, discussions of the menstrual benefits of OCPs
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also establish the goals of particular medical treatments. Providing women with “shorter
periods” was one of the treatments offered by the OCPs to suggest that a woman can
ensure her the problem of long periods can be made shorter by being on the OCP.
“Lighter periods” and “predictable periods” were also discussed as advantages of
medical treatment. Setting achievable benchmarks for women (“shorter,” “lighter,” and
“predictable” periods) secures the need to treat women’s menstrual symptoms and
relieve them of seemingly cumbersome menstrual management routines. Messages of
“relief” were quite common on the websites I analyzed. To analyze the relief messages
imparted by the websites during DTCPA, I took each type of relief mentioned and
categorized it by its main message. The table below shows how websites characterized
the problems that needed to be treated and the goals or benchmarks (i.e., “relief”)
desired.
Table 13: How the Pill Manages/Treats Menstruation
Name of the Pill
How the Pill
Type of Problem Solved
Manages/Treats
Menstruation
Beyaz

- Treat PMDD (PreMenstrual Dysphoric
Disorder)

-PMDD is a menstrual related
disorder

Generess Fe

- Shorter periods

-Long periods

- Lighter periods than
usual

-Heaviness of the flow
-Variation of the blood flow’s arrival

- Predictable periods
- Average length of cycle is
four days
- Lighter periods over time
- Periods starts for most
woman on the 27th day
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- Average intensity of the
periods was lighter over
time
Lo Loestrin Fe

- Shorter periods

-Long periods

- Lighter periods

-Heaviness of the flow

- Lighter than normal
- Fewer than two days on
average
Minastrin 24 Fe

- Has the same bleeding
profile as a discontinued
OCP

-Long periods

- Shorter periods

-Heaviness of the flow

- Average cycle length is
under 3 days by 6th cycle
- Less bleeding
Natazia

- First and only clinically
proven to help heavy
monthly periods

-Heaviness of the flow

- Lighten heavy monthly
periods
- Treatment of heavy
menstrual bleeding not
caused by other conditions
- Reduces heavy periods
ORTHO TRICYCLEN LO

- Predictable periods

-Variation of the blood flow’s arrival

- Lighter periods

-Heaviness of the flow
-Decreases pain

- Reduced menstrual
cramps
-Long periods
- Shorter periods
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- Regulates menstrual
cycle
SAFYRAL

- No discussion of
menstruation/any
menstrual process

-None

YAZ

- Treats PMDD (PreMenstrual Dysphoric
Disorder)

-PMDD is a menstrual related
disorder

The Symptom Checker Quiz and Treatment
Natazia’s website was the only website with a symptom checker quiz, titled “Heavy
Periods? Take the Quiz”. This interactive feature makes Internet DTCPA unique, as the
consumer is able to take this quiz to see if they are facing the symptom (and thus,
“problem”) of “heavy periods”. However the quiz also goes one step further and sets the
stage for medicalization by offering a clear treatment or solution to the problem. The
introduction to the quiz asks, “Do you know the facts about heavy periods and
Natazia®? Take our true/false quiz to find out. Talk to your healthcare provider to
determine if your bleeding is heavier than normal” (www.natazia.com). From the
introduction on, this quiz demonstrates all the aspects of Conrad’s medicalization
framework as follows: “Do you know the facts about heavy periods” (labeling the
problem from a medical framework where heavy periods are the symptom), “and
Natazia” (defining the available treatment or solution) and “Talk to your healthcare
provider to determine if your bleeding is heavier than normal” (involve medical expertise
to treat the problem). Here, I discuss the quiz to highlight how OCP websites define
menstruation as negative (therefore naming the problem and beginning the process of
medicalization), provide treatment (in the form of the OCP Natazia, thus continuing the
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process of medicalization) and inform consumers to seek the assistance of healthcare
providers (therefore, completing the process of medicalization by involving experts to
treat these menstrual symptoms using Natazia). The symptom checker quiz has five
statements that are answered by using the answers “True” or “False”. Given below is
the quiz listed on Natazia’s website, the statements that comprise the quiz are as
follows:
1) Many women believe heavy periods are “normal” and do not seek treatment.
2) Heavy monthly periods (also known as heavy menstrual bleeding) affect millions
of women in America each year.
3) Natazia is the only birth control pill that is also FDA-approved to treat heavy
monthly periods.
4) Soaking through one or more pads or tampons every hour, or even having to
double up on protection, is considered a “heavy period.”
5) Restricting daily activities due to heavy bleeding is something that all women
have to deal with. (www.natazia.com)
The website contends that the correct explanation to the first statement is “True” and
this explanation follows:
Although common, heavy periods should not be considered normal. Many
women do not realize that they can get help, and some are too embarrassed to
talk about it. Some women have always had heavy periods, so they feel this is
just what their periods are supposed to be like. Talking openly about your heavy
periods with your doctor or even a nurse during your office visit helps them better
understand what you’re going through, and can lead to treatment options that
can help (www.natazia.com).
The explanation provided above implants in women the idea that their menstrual cycle
could actually be “heavy”. The process of medicalization is beginning here: heavy
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periods are being described as a medical condition that should not be considered
“normal”, therefore labeling a bodily experience as negative and in need of treatment. A
definition of a “normal” period is also not given, which lends to women’s assumption that
they might be “abnormal” too. “Some women have always had heavy periods” also
disabuses women of their own assessments, and encourages them to second-guess
their ability to assess their own levels of normality.

Within the definition of heavy

periods as abnormal, there is also mention of “treatment options that can help.” In the
explanation of what heavy periods are, then, women are also encouraged towards
action, and towards seeing their health care provider to discuss the problem, which is
another aspect of medicalization. Thus, the definitions of potentially negative and
abnormal symptoms prescribe women’s actions (i.e., visiting the doctor for treatment) as
well. Visiting the doctor is suggested openly in the sentence “Talking openly about your
heavy periods with your doctor or even a nurse during your office visit helps them better
understand what you’re going through, and can lead to treatment options that can help”
(www.natazia.com). Women are being reminded that they can consult the experts (i.e.
“”doctor or even a nurse”) for two main reasons – to inform the medical providers about
the “heavy periods” and to also obtain “treatment” that will help.
The second quiz statement is “Heavy monthly periods (also known as heavy
menstrual bleeding) affect millions of women in America each year” and the correct
answer is also “True”. The explanation for the answer states, “One of the most common
health issues women report to their healthcare providers is heavy periods. In America,
heavy periods affect more than 10 million women per year, or about one in every 5
women” (www.natazia.com). By using the term “health issue” to describe heavy periods,
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the normality of periods begins to be questioned and the “problem” becomes defined
within a medical framework. According to Arney and Rafalovich (2007), a “you-are-notalone-in-your-suffering mindset” is typically created through DTCPA. This mindset is
conveyed through the advertisements and encourages consumers to think of
themselves as part of a community of sufferers (Arney & Rafalovich, 2007). Numbers
also remind women that they are not alone in their potential pain and suffering, and that
they could be among the one in five women affected by this “health issue”; therefore,
they should maybe consider their own experience as abnormal and in need of
intervention. Therefore, the need for treatment is once again being established here.
The third quiz statement, also “True,” suggests that “Natazia is the only birth
control pill that is also FDA-approved to treat heavy monthly periods”. Subsequently, the
statement is explained:
Natazia is the only birth control pill approved by the FDA to help lighten heavy
monthly periods not caused by another condition of the uterus, such as fibroids
or polyps. For women who choose the Pill for birth control, Natazia could be a
treatment option for those experiencing heavy periods (www.natazia.com).
The second component of medicalization is visible here in the form of establishing
the need for treatment for symptoms, specifically in the promotion of Natazia. This
discussion of treatment comes sequentially, after the discussion of the actual problem
(and the lessening of women’s expertise about what is normal or abnormal) in the first
and second questions of the quiz. The fourth statement on the Natazia quiz is: “Soaking
through one or more pads or tampons every hour, or even having to double up on
protection, is considered a “heavy period” (www.natazia.com). The answer is given as
“True”, with the explanation that, “While it’s important to talk to your healthcare provider
about your heavy periods to ensure it’s not something more serious, there may be
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treatment options that can help” (www.natazia.com). When women are also informed
that “there may be treatment options that can help,” women are also encouraged to see
that the problem can be solved through medical intervention. As mentioned previously,
the encouragement to talk to a healthcare provider is also another aspect of the process
of medicalization; and there is a pressure to seek medical expertise for the problem, in
addition to an intervention or treatment. Seeking expertise and seeking treatment, then,
go hand in hand in securing the medicalization of menstruation.
The last statement on the quiz was “Restricting daily activities due to heavy bleeding
is something that all women have to deal with.” The correct answer is “False” and that
answer is followed by this text: “If your life is significantly impacted by your heavy
periods, it’s time to talk to your healthcare provider. Restricting daily activities due to
fear of “leaking” or bleeding through clothing isn’t normal. It may be time to see what
treatment options are available that could be right for you” (www.natazia.com). Here the
symptoms of menstruation are given again in the form of “significantly impacted by your
heavy periods”, “restricting activities due to fear of “leaking”, and “bleeding through
clothing” (www.natazia.com). Women are informed that these symptoms “isn’t normal”
for them to experience. This last statement infers that there are also negative lifestyle
consequences if women are experiencing these symptoms, further establishing the
need for treatment. This need for treatment is imparted to women through statements
such as, “It may be time to see what treatment options are available that could be right
for you” (www.natazia.com). Women are encouraged to seek medical advice through
the statement “….it’s time to talk to your healthcare provider” (www.natazia.com). This
portion has numerous elements of medicalization of menstruation in it such as defining
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and providing symptoms of a problematic period to the consumer, creating the need for
treatment and actively telling consumers to seek treatment from the medical experts.
Treatment of Other Symptoms
In this section, I further discuss how the websites demonstrate the treatment of
other symptoms of menstruation such as longer periods, heavier periods, predictable
periods, menstrual pain and PMDD using OCPs. This section also covers how the need
for treatment is established and the action that is often encouraged (i.e., seeing a
healthcare provider) to obtain treatment. According to the U.S. Department of Health
and Human Services, a woman’s menstrual cycle (when untreated) can last for up to
seven days (U.S. Department of Health and Human Services, 2009). However, the
websites demonstrate that a shorter period is a benefit of taking OCP and it is also
inferred that shorter periods should be a goal for women. Using medical intervention
(OCPs) to reduce the actual number of menstruating days (shortening the cycle) was
shown as a major form of relief on the websites, thus treating the problem of long
periods and setting a goal or solution of “shorter” periods. Shorter periods as a way in
which treatment is successful was discussed once on the website of Minastrin 24 Fe,
once on the website of ORTHO TRI-CYCLEN LO, eight times on the website of
Generess Fe, and 21 times on the website of Lo Loestrin Fe (total of 31 times). Three
websites (e.g., Lo Loestrin Fe, Minastrin 24 Fe and Generess Fe) also provided
information about exactly how short a woman’s period can become if she takes that
particular OCP.
Lighter periods were also discussed on five websites (Lo Loestrin Fe, Generess
Fe, Natazia, Minastrin 24 Fe and ORTHO TRI-CYCLEN LO) as a goal or benchmark
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that women should desire, and the relief or solution that OCPs bring. It was discussed in
this context the following number of times: 19 times on the website of Natazia, 12 times
on the website of Lo Loestrin Fe, eight times on the website of Generess Fe , once on
the website of Minastrin 24 Fe and thrice on the website of ORTHO TRI-CYCLEN LO
(total of 43 times). Predictable periods were shown as a relief provided on the website
of two OCPs– ORTHO TRI-CYCLEN LO and Generess Fe. ORTHO TRI-CYCLEN LO’s
website focused the most on predictable periods as a way their OCP manages
unpredictable periods when compared to the rest of the websites. The ability of the
OCPs to provide a woman with predictable periods was mentioned seven times on their
website and six times on the website of Generess Fe, for a total of 13 times.
A clear treatment plan was established by the pharmaceutical companies when it
comes to using the OCP to provide women with a shorter, lighter and predictable
period. Thus, treatment solves problems and creates better menstruation (i.e., better
menstruation being the goal of treatment). One of the main steps of the treatment plan
includes providing solutions for menstrual problems using the OCPs. Another aspect of
the treatment plan that reinforces medicalization is to include the healthcare provider’s
expertise because women are not seen as experts on their own bodies. For example:
Minastrin 24 Fe’s websites tells women that if their periods are “unusually heavy” or
“last more than a few days”, women are asked to “Call your healthcare provider…” if this
happens. Treatment using Minastrin 24 Fe’s is described as providing women with
“shorter periods averaging fewer than three days” (www.minastrin24.com), thus treating
the problem of a longer period. Furthermore, “Lighter periods with less bleeding” is
established as another form of proven treatment to help women with their periods
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(www.minastrin24.com). All aspects of medicalization are visible here. Women are not
only informed of the symptoms of a problematic menstruation to show that treatment is
needed, they are asked to call their healthcare provider for help for the symptoms.
Additionally, women are also told how treatment benefits them.
Similarly, the website of ORTHO TRI-CYCLEN LO informs women to ask their
physicians “How do I know if my period is normal?” (www.thepill.com). Asking the
physician, “How do I know if my period is normal?” shows that women should be
concerned about their periods and should rely on physician expertise to determine
whether their “period is normal” (www.thepill.com). The aspect of medicalization visible
here is that women are taught to rely on the expertise of medical professionals about
their own bodily experience. Furthermore, asking women to think if their periods are
normal implants the idea of an abnormal period, and the need for treatment. Two ways
in which treatment is successful for a period that might not be “normal” is suggested:
One is that ORTHO TRI-CYCLEN LO can make the periods “shorter” and another is
“predictable” (www.thepill.com). The two actions of medicalization happening here are
encouraged are women having to consult their physician to determine the normalcy of
their period (thus checking the symptoms by use of medical expertise). Another
characteristic of medicalization occurring is the availability of solution to the problem in
the form of a shorter and predictable period.
Furthermore, on the website of ORTHO TRI-CYCLEN LO, the establishment of a
treatment method for this problem an unpredictable period is further conveyed through
“Do you want a birth control pill that gives you a high level of effectiveness and a low
level of hormones? How about one with these benefits and one that may provide more
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predictable periods? Here's why ORTHO TRI-CYCLEN® LO may be right for you”
(www.thepill.com). The usage of the term “right for you” sends the impression that there
is a match between women’s menstrual management problems and this particular OCP
medication. Furthermore, women are clearly informed that the OCP is the solution for
this problem as it makes their period more predictable. Women are being explicitly
asked if they want a form of medical intervention that may “provide more predictable
periods?”. Medicalization is occurring here because of the offering of a clear medical
treatment solution to the problem. This is further apparent in the quote “If your periods
have been bouncing all over the calendar, you can look forward to a more predictable
period with each month that you use the Pill. Remember to always take the Pill on time
to keep cycles more regular” (www.thepill.com).

Here, the treatment method for

unpredictable periods is established clearly which is to “use the Pill” and “always take
the Pill on time” (www.thepill.com).
As mentioned earlier, Natazia’s symptom checker quiz portrayed all aspects of
medicalization such as naming and treating the problem along with encouraging
healthcare provider’s expertise in the treatment portion. However, Natazia’s website
further states, “When you have concerns about your period, you should always tell your
healthcare provider, even if you aren’t asked first. Don’t be afraid to let your healthcare
provider know exactly what you’re experiencing and how your periods impact your life”
(www.natazia.com). Additionally, the website states “If your life is significantly impacted
by your heavy periods, it’s time to talk to your healthcare provider. It may be time to see
what treatment options are available that could be right for you” (www.natazia.com).
One of the main aspects of medicalization occurring here is not just informing women
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their periods can be problematic, but also setting up the prescription of action. The
prescription of action is set up in two ways – one way is to offer a clear treatment and
solution to the menstrual woes by informing women that “treatment options are
available”. The second prescription of action is seeking the expertise of healthcare
providers to support the need for treatment. In addition, “even if you aren’t asked first”
sends the message that women should seek advice from medical experts at every turn.
Statements such as “you should always tell your healthcare provider” and “Don’t be
afraid to let your healthcare provider know exactly what your experiencing” informs
women that they must seek that help about their period “concerns”. This is again
evident as Natazia’s website states, “Talking openly about your heavy periods with your
doctor or even a nurse during your office visit helps them better understand what you’re
going through, and can lead to treatment options that can help,” and “Talk to your
healthcare provider to determine if

your bleeding is heavier than normal”

(www.natazia.com). In both these instances, women are being taught to question their
normality and seek help from doctors in order to establish bodily knowledge and
treatment plans.
One of the questions listed for women to ask their healthcare provider on the
website of Lo Loestrin Fe is, “Will Lo Loestrin Fe make my periods short and lighter?”
(www.loloestrin.com). Two elements of medicalization are occurring here. Firstly, a clear
treatment plan is being developed by the pharmaceutical company through having the
consumer know if the OCP can treat their period and make it “short and lighter”
(www.loloestrin.com). Secondly, the consumer is asked to involve the expertise of the
healthcare provider in deciding if Lo Loestrin Fe is a good treatment for them. The ability
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of Lo Loestrin Fe to solve menstrual problems for women is further highlighted on their
website through a very own menu called “What will my periods be like?”. Here a need
for treatment using the OCP is established by pharmaceutical company by discussing
how relief can be achieved from regular menstruation. Women are blatantly informed
“Go low for short, lighter periods” (www.loloestrin.com). Then women are informed that
they will experience a period “fewer than two days per cycle on average” if she takes
the OCP (www.loloestrin.com). This information of “less than two days” was mentioned
a total of five times on this website. The repetition of this information emphasizes the
importance placed on this aspect of menstrual suppression. Furthermore, the repetition
feeds the idea of a shorter period to women over and over again as being a major relief
provided by the OCP. There is also an illustration of a purple drop with “<2 days” written
in the drop. Next to this visual image is written the words, “Some women had a period
that lasted LESS THAN 2 DAYS per cycle on average” (www.loloestrin.com). The use
of capital letters for the phrase, “LESS THAN 2 DAYS,” also demonstrates the
emphasis placed on this advantage by the pharmaceutical company. The message here
is that Lo Loestrin Fe is successful in shortening a woman’s OCP to less than two days
(i.e., effectiveness of treatment using the OCP) which allows women to not have to
tolerate the problem of long periods and can achieve relief through treatment.
A clear treatment method is established on Generess Fe’s website when it gives the
solution of reducing the “average intensity” of menstrual flow by using their OCP.
Generess Fe’s website also affirms that, “Women taking Generess Fe had short
periods—on average about 4 days. Women also reported their periods to be lighter than
normal. Plus, they found their periods to be lighter over time.” (www.generess.com).
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This information is placed under the menu titled, “What can Generess Fe do for you?”
indicating the fact that this OCP offers a concrete solution to problems associated with
menstrual management. The main aspect of medicalization here is showing the
consumer how Generess Fe can help treat their menstrual problem, thus establishing a
clear treatment method. Another aspect of medicalization of menstruation evident on
the website of Generess Fe is the encouragement for women to seek medical expertise.
The website of Generess Fe states, “Ask your doctor about Generess Fe for pregnancy
prevention

with

short,

lighter,

predictable

periods—all

in

a

low-dose

pill”

(www.generess.com). It is interesting to note that the consumer is being directed to ask
about the product not only as a contraceptive but also a product that provides “short,
lighter, predictable periods” (www.generess.com).
Another relief that was mentioned twice was menstrual pain management while
on the OCP. It was mentioned both times only on the website ORTHO TRI-CYCLEN. It
states on the website that “Menstrual cramps are usually less severe when you're on
the Pill” (www.thepill.com). Furthermore, it attests that “The hormones in ORTHO TRICYCLEN® LO also help to regulate your menstrual cycle, so your periods may be more
predictable and pain or other symptoms during menstruation may be encountered less
frequently” (www.thepill.com). Multiple aspects of medicalization are evident here.
Medical intervention (here, OCP use) brings relief from symptoms, and we read that the
use of ORTHO TRI-CYCLEN LO can lead to “symptoms during menstruation [being]
encountered less frequently”. Women are informed exactly how the OCP can help
menstrual cramps and bring relief – by making them “less severe”. Therefore, another
aspect of medicalization that is clear here is the specific treatment of the symptom using
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OCPs (i.e., an established treatment plan). It is also expanded to illustrate that the
hormones in the OCP helps to regulate the menstrual cycle (regulation is the form of
treatment) which leads to reduction of “pain or other symptoms during menstruation”
(how the treatment alleviates the symptom). Medical expertise is also recommended as
it says further “If you think ORTHO TRI-CYCLEN® LO may be right for you, set up an
appointment with your gynecologist or healthcare professional to discuss whether you
are a good candidate” (www.thepill.com). Another aspect of medicalization is visible
here which is not only the encouragement of women to think about the match between
their symptoms and the available treatment, but also the reminder that the healthcare
provider must be consulted.
Only two websites discussed treating premenstrual dysphoric disorder (PMDD)
using their OCPs (YAZ and Beyaz). The websites for YAZ and Beyaz state:
What are Beyaz® and YAZ® prescribed for?
For women who choose the Pill for birth control, Beyaz and YAZ are approved to:
-Treat premenstrual dysphoric disorder (PMDD)
-Beyaz and YAZ are not approved to treat Premenstrual Syndrome (PMS), a less
serious set of symptoms occurring before your period (www.beyaz.com;
www.yaz-us.com)
According to the latest edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5), PMDD is now officially classified as a psychiatric disorder (Gotlib &
LeMoult, 2014).
The decision to move premenstrual dysphoric disorder to the main body of DSM5 was based on evidence that 2% to 5% of menstruating women experience a
unique depressive disorder that begins following ovulation, remits within several
days of menses, and leads to significant interference in daily life. A diagnosis of
premenstrual dysphoric disorder requires at least five clinically significant
symptoms that occur repeatedly during the premenstrual phase of the cycle and
that remit at or shortly after the onset of menses (APA, 2013). At least one
symptom must reflect disturbance in general mood: mood lability, irritability,
dysphoria, or anxiety. In addition, individuals must endorse at least one of the
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following physical/behavioral symptoms: anhedonia, difficulty concentrating,
lethargy, appetite changes, sleep changes, overwhelmed feelings, and physical
symptoms. These symptoms must have occurred in most of the menstrual cycles
during the past year and must be severe enough to cause marked impairment in
work or social functioning. (Gotlib & LeMoult, 2014:196)
Earlier, in this chapter, I discussed the controversy that led to adding LLPDD into
the appendix of the DSM-3 as a mental illness. According to Knaapen and Weisz
(2008), one of the key players who wanted this change was pharmaceutical companies
because “pharmaceutical companies needed specific diagnostic categories around
which to develop and sell their products” (p.127). When the DSM-4 was created many
years later, LLPPDD was changed to PMDD (Knaapen & Weisz, 2008). As per the
literature given above the latest DSM-5, it is clear that PMDD is now seen as a medical
condition that affects menstruating women in a psychiatric manner. Despite PMDD
being included in the DSM-5 as a significant condition, there is no expansion of the
information about its symptoms on the current websites of both YAZ and Beyaz. One of
the main facets of medicalization is treating the problem that is defined by medical
terms. Even though PMDD is not defined by medical terms here (in the form of
symptoms), medicalization is visible because it says that YAZ and Beyaz are able to
treat PMDD. The establishment of a clear treatment method using the OCPs allows for
the matching of condition (PMDD) to its solution (treatment using OCPs). Furthermore,
it is clear that pharmaceutical companies have mentioned earlier they are not approved
to treat PMS but approved to treat PMDD. This shows that since the medical community
has backed off labeling PMS as a medical condition and have established PMDD now
as the medical conditions instead, pharmaceutical companies are being careful that the
treatment they are providing aligns with the medical diagnosis.
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Chapter Summary
In this chapter, I examined evidence of the medicalization process, as present on
eight OCP websites. Numerous features of medicalization became visible within the
data on these websites. First, naming the problem in medical language was evident in
the text on the websites. OCP websites portrayed symptoms of menstruation and
determined that those symptoms were potentially negative and abnormal. Second,
websites also defined solutions for the problems of menstruation and suggested
matches between menstrual symptoms and medical treatments, through the
advertisements for OCPS. Third, website text indicated that medical providers, not
women, were experts on women’s bodies, and that women should consult these experts
whenever possible. Women are told to take the OCP “as directed by your doctor” and
“see what treatment options are available” which demonstrates that doctors are
considered as the authority that should be consulted about this matter. Phrases such
as “tell”, “ask” and “talk” are used to encourage women to bring their menstrual
problems forward to their healthcare providers. The next chapter presents a summary of
the findings in this dissertation and potential conclusions of this research, in addition to
the contributions and limitations of this study and future recommendations.
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CHAPTER 7 - CONCLUSIONS
Because DTCPA is increasingly used to market pharmaceutical products, it
provides important messages to consumers, and these messages include an emphasis
on the freedom to choose and change their lives by purchasing the advertised product
(Schudson, 2013). Previously, DTCPA operated primarily through print and broadcast
media but, today, pharmaceutical companies are using the Internet as one of their
biggest DTCPA platforms (Liang & Mackey, 2011). According to The Pew Research
Internet Project (2013), searches for drug information were one of the major types of
health-related searches on the Internet. Many pharmaceutical companies have
established websites about the medications they manufacture. In this study, online
DTCPA websites for traditional OCPs (i.e., 21 or 24 hormone pills followed by 7 or 4
non-hormone pills) were examined utilizing qualitative content analysis techniques.
Eight traditional OCP websites were included in this exploratory study. These
eight websites advertised the following OCPs: Beyaz, Generess Fe, Lo Loestrin Fe,
Minastrin 24 Fe, Natazia, ORTHO TRI-CYCLEN LO, SAFYRAL and YAZ. The two
research questions that guided this study were: (1) How are traditional OCPs portrayed
and characterized on online DTCPA websites? (2) What evidence of medicalization
present on these online DTCPA websites?
Major Themes from the Study
One of the major themes that arose from the study is that descriptive colors,
images, slogans and consumer incentives helped pharmaceutical companies appeal to
their female audience. In addition, some descriptive characteristics promoted the OCPs’

125
benefits, to further encourage prospective consumers to consider traditional OCPs.
Purple and white were the two colors most commonly found on the websites. While
purple is shown to appeal to female audiences when it comes to drugs, white is also a
popular color used within online DTCPA (Charbonneau, 2010; Greenslit, 2002).
Therefore, pharmaceutical companies are aligning with color choices that have been
proven effective in the past. Slogans relayed information not only about the benefits of
the OCPs, but also the product’s effectiveness. Benefits of the OCPs were conveyed
through slogans such as “Generess Fe is birth control with benefits” and “Natazia®, the
First and Only Birth Control Pill Clinically Proven to Help Heavy Monthly Periods”
(www.generess.com; www.natazia.com). Another slogan is “Reliable Birth Control,”
followed by “Daily Assurance” on the website of ORTHO TRI-CYCLEN LO
(www.thepill.com). Generess Fe’s slogan, “Little pill. Big difference,” suggests that even
though the OCP is not difficult to take, it can help women make changes in their lives for
the better (www.generess.com). Use of terms such as “reliable”, “little”, “big”, “first and
only”, “clinically proven”, “help” and “assurance” imparts a message the OCP is failproof, likeable and trustworthy for women.
Images of women on the websites suggest that OCP users are happy, free from
burden, and active. The images on the websites showed women engaging in the
following activities: smiling, laughing, sky diving, water diving, snowboarding, bungee
jumping, walking the dog, walking with a box that says Rx, jogging, having a cup of
coffee and relaxing at home. Some of the items that surrounded the images were the
symbol ♀, a graduation hat, a graduation diploma, a microscope and a female business
suit, inferring success in paid work and education. Medley-Rath and Simonds (2010)
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also propose that contraceptive DTCPA depicts women as successful people who are
doing well for themselves. Women depicted in online DTCPA for these eight OCPs are
smiling and relaxing. A sense of adventure is imparted through the images of women
who are snow-boarding, sky diving, water diving and bungee jumping. Moreover, it is
inferred that these women’s lives are unaffected and uninterrupted by the worries of
pregnancy and/or menstruation, thus sending a subtle message to women that a
traditional OCP prescription allows them the freedom to control their own lives and stay
free from burden. Therefore, images function to not only promote the product but also
appeal to female audiences by projecting the possible lifestyles and successes that are
possible if women are prescribed and take a traditional OCP.
The websites I analyzed also made it very easy for prospective consumers to
take advantage of consumer incentives (available immediately upon entry to the
websites in most cases), thus increasing the attractiveness of OCPs. With the exception
of the website for Natazia, all of the other websites placed consumer incentives at eyelevel or at the very top of the homepage of the websites. Furthermore, the consumer
incentives could always be downloaded online and used right away. Much of the look
and feel of the DTCPA websites, such as the colors, images, slogans and consumer
incentives, is constructed purposely to appeal to women as soon as they access the
websites. Overall, the eight DTCPA websites are constructed to efficiently and
effectively promote the likeability and affordability of OCPS, in addition to the primary
benefits of OCPs.
The second theme that emerged from this study, then, is the importance placed
on the benefits of traditional OCPs and, relatedly, how benefits were given more

127
importance than the risks and side-effects of OCPs on these online DTCPA websites.
Four types of information about documented drugs benefits were present on the
websites: pregnancy prevention, menstrual benefits, low amounts of hormones, and
presence of folate. Pregnancy prevention was the only benefit that was mentioned on all
the websites (for a total of 136 times). Except for the website of SAFYRAL (which did
not mention menstruation), all seven other websites showcased the menstrual
management benefits of OCPs (i.e., shorter, lighter and predictable periods for a total of
91 times). Low dosages of hormones was mentioned as a benefit on three websites (for
a total of 41 times): Lo Loestrin Fe, ORTHO TRI-CYCLEN LO, and Generess Fe. The
presence of folate was mentioned as a benefit on two websites (for a total of eight
times): SAFYRAL and Beyaz.
Two types of risk information were present on the websites I analyzed. The most
important risk information included the warnings given to smokers who are using the
OCPs (mentioned a total of 63 times across all eight websites). The second type of risk
information was about other, varied medical side effects of OCPs. For example, serious
cardio-vascular events such as heart attacks, strokes and blood clots were mentioned
as risks on all the websites (totaling 144 mentions for cardio-vascular events including
heart attacks, 105 times for strokes and 128 times for blood clots).
Benefit information was always placed at the top or middle of the home pages of
websites, compared to side-effect information that was placed at the bottom of all eight
websites. This supports Huh and Cude’s (2004) findings on the placement of benefit
and risk information. The only exception that the websites of YAZ, Beyaz, Natazia and
SAFYRAL placed warnings to smokers in a prominent position, at the top of the home
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page on these four websites. Some of the other most common side-effects were
headaches/migraines, vomiting, nausea, mood changes and acne. Information about
these side effects was found at the very bottom of the home page on the websites that I
studied. This is of particular concern because this information could be easily
overlooked when websites are accessed, but it seems that this placement is very
purposeful. Moreover, benefit information was repeated quite frequently across menus
and types of text on the websites, whereas risk information was not repeated as often.
It is also interesting to note that there was no discussion on these eight websites
of the dangers of high dosages of estrogen (to parallel the discussion of the benefit of
low dosages of hormones), although the discussion of low dosages of hormones on a
few websites certainly hints that high dosages are harmful. The medical literature
advocates for lower dosages of estrogen, for instance, when stating that a “reduction in
estrogen in newer preparations [of OCPs] has helped to reduce the incidence of
prothrombotic and prohypertensive side effects” (Chadwick, Burkman, Tornesi &
Mahadevan, 2012, p.4). Pharmaceutical companies creatively share beneficial
information while downplaying parallel risks on their DTCPA websites, and pay keen
attention to how benefit information - instead of risk information - is shared.
Another way that information on risks was minimized was in the language used
on these DTCPA websites. When benefits were discussed, detailed numerical data
was provided to paint benefits in a positive light, such as “99% effective,” or “menstrual
bleeding was reduced over 90 days by an average of 72% in one study and 78% in the
other” (www.loloestrin.com; www.natazia.com). However, when risks were discussed,
such detailed statistics were not provided to the consumer. During my analysis, it
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became clear that risks were designated by a general lack of importance, when
compared to the emphasis placed on benefits.
The third theme found in the study is that pharmaceutical companies emphasize
and reinforce the medicalization of menstruation, specifically by naming menstruation as
a problem, offering OCPs as a form of treatment for menstrual problems, and
encouraging women to view their healthcare providers as experts on menstruation and
menstrual management. It has already been suggested in existing literature that DTCPA
is a driving force of medicalization, whereby conditions that are usually benign are now
being treated with medicines (Conrad, 2007). Menstruation was defined a “problem” for
women on the websites through the usage of terms. For instance, untreated menstrual
flow was defined as possibly “heavy”, “unusually heavy”, “more than a few days [length]”
and “bouncing all over the place”. In addition, on some websites, having to double up on
menstrual protection, restricting daily activities, bleeding through clothing; missing work
and staying home were also listed as possible menstrual problems. Johnston-Robledo,
Barnack and Wares (2006) agrees that the biomedical model constructs menstruation
as a condition that needs to be managed medically, and also as an inconvenience that
affects other facets of the woman’s well-being. My findings confirm Johnston-Robledo,
Barnack & Wares’ findings.
Offering OCPs as treatment for menstrual problems and promoting healthcare
providers (especially doctors) as experts were prevalent actions on the websites. Two of
the websites studied also had tabs that discussed menstruation exclusively (i.e., Lo
Loestrin Fe’s tab “What will my periods be like?” and Natazia’s tabs “Heavy Periods?
Take the Quiz”, “Natazia Can Help With Heavy Periods” and “Talk to Your Doctor About
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Heavy Periods”). The websites in this study hailed OCPs for their ability to provide
women with shorter, lighter and predictable periods (three related yet separate benefits
garnered from treatment). Menstrual benefits gained through OCP treatments were
discussed quite commonly on the websites (i.e., shorter periods were mentioned 23
times, lighter periods were mentioned 53 times, and predictable periods were named 13
times). The treatment of PMS was not highlighted on most websites, but PMS was
described as a set of (not so serious) symptoms on the websites of YAZ and Beyaz.
However, these websites informed women that OCPs were “not approved to treat PMS”
(www.beyaz.com; www.yaz-us.com). Treatment of PMDD was discussed as a benefit
twice on the websites of YAZ and Beyaz without explanation of what constitutes PMDD,
thus potentially leaving consumers to make their own assumptions about PMDD versus
PMS. There should be further research into the ways in which PMS and PMDD are
characterized

with

online

DTCPA

(i.e.,

in

advertising

forums

within

which

women/consumers cannot ask for additional information).
Within these eight websites, pharmaceutical companies informed women
explicitly to ask their health care providers about OCPs as a treatment for their
menstrual problems. This was evident in phrases, such as “Ask your doctor about
Generess Fe for pregnancy prevention with short, lighter, predictable periods—all in a
low-dose pill” (www.generess.com), and “If your life is significantly impacted by your
heavy periods, it’s time to talk to your healthcare provider. It may be time to see what
treatment options are available that could be right for you” (www.natazia.com). It is
already documented that the treatment of menstrual problems using hormonal methods
such as OCPs is encouraged both by the medical and pharmaceutical community
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(Coutinho & Segal, 1999; Freeman, 2010; Harel, 2006; Lin & Barnhart, 2007; Panay,
2011; Shulman & Kiley, 2011); thus my analysis confirms this finding that OCPs are
characterized as a specific treatment option.
Women were also encouraged to consult their healthcare providers a total of 13
times on the websites. Pharmaceutical companies are setting up an ideal patient-doctor
relationship, within which women (the patients) consult medical experts (i.e. doctors)
about processes that they once dealt with on their own. However, Hoffmann and
Tarzian (2001) state, “The feminist literature is rife with examples and criticism of
women’s voices not being heard or considered credible in the male-dominated healthcare system” (p.20). Furthermore, feminist literature shows that women have a hard
time trusting their physicians due to their voices being unheard (Sherwin, 1992). When
pharmaceutical companies ask women to trust their doctors as medical experts and
speak to them about their “menstrual problems”, they are reinforcing the concept that
physicians are ultimate expert in women’s bodies rather than the woman herself. The
well-documented reality is, though, that physicians and women often do not have an
ideal or trusting relationship.
There was also evidence of professional dominance within my data on the
Natazia website. Natazia’s website states “Talking openly about your heavy periods with
your doctor or even a nurse during your office visit helps them better understand what
you’re

going

through,

and

can

lead

to

treatment

options

that

can

help”

(www.natazia.com). In this case, the phrase “or even a nurse” indicates that the doctor
should be women’s first choice for a medical expert when dealing with problems of
menstrual management. Hartley (2002) proposes that, “Physician professional
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dominance can be understood as the ability of the medical profession to exert control
over potentially competing professional groups, as well as over the larger institutional
domain” (p.180). According to the theory of professional dominance, then, physicians
are considered to have the main role in diagnosing illness and treating women’s
menstrual problems. Pharmaceutical companies have the power to reinforce
professional dominance, in this case through online DTCPA.
Limitations of this Study
For this study, I used qualitative content analysis techniques to illustrate the
portrayal, characterization and medicalization present on the DTCPA websites for eight
traditional OCPs. One of the major limitations of this study is the small number of
websites that were studied. By using only eight websites for this study, I may have
missed important variations in online DTCPA websites for OCPs. Only eight traditional
OCP websites were available to be analyzed at the time this study was proposed,
however. Even though these websites were analyzed in detail, it still remains a very
small sample size. With online information constantly changing, this study also
experiences the limitation that some of the content might not be available for consumers
today in the way it was available in 2014, when data collection took place. In addition,
because of time and space constraints I did not engage in as much comparison of the
eight websites as could have been possible; therefore a more comparative second
study is needed. Nonetheless, in-depth textual data was gathered from the eight
websites in an unobtrusive manner, making this a very feasible study.
A third limitation of this study is that three OCPs experienced a change in
pharmaceutical company ownership, between Fall 2014 and the time that this
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dissertation was completed. When data collection occurred, Lo Loestrin Fe, Generess
Fe and Minastrin 24 Fe were manufactured by Actavis Pharma. Today, all three of
these OCPs belong to the pharmaceutical company Allergan, due to the merger of
Actavis Pharma with Allergan in 2015 (http://www.allergan.com/news/news/thomsonreuters/actavis-completes-allergan-acquisition, Retrieved: March 2016). This change of
ownership could be significant for this study, as this change in ownership might change
how the same OCPs are advertised through the DTCPA websites now.
Another limitation of this study is that the data were collected and analyzed
before the Affordable Care Act mandated that insurance companies cover the entire
cost of OCPs. As of July 2015, with some exceptions for religious employers and certain
health plans, insurance companies are now required to cover OCPs entirely
(http://obamacarefacts.com/obamacare-birth-control/,

Retrieved:

March

2016).

Following this new mandate, the advertisement of OCPs could be different. Finally,
researcher bias is another drawback of qualitative research. I was aware of the
subjective of the nature of qualitative research before the study began and, therefore,
tried to remain as objective as possible when analyzing the data. In order to achieve
this, I had a second individual look at the website data and coding strategies to confirm
that my data analysis was accurate. This process ensured that I remained as objective
as possible during the data collection and analysis process. To be fair, DTCPA
advertising of any pharmaceutical product may follow a particular format and stress
benefits over risks. DTCPA advertising is utilized to sell pharmaceutical products and,
therefore, we may find very similar findings if we visited DTCPA websites for heart
medications, prostate medications, cold medications, etc. A future researcher could
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engage in a comparative study to see if DTCPA advertising always medicalizes to the
same degree regardless of type of product, or if products related to women's health may
be more medicalized by DTCPA than other products
Future Recommendations
I have several recommendations, both for research and future DTCPA policy.
One of the major findings of this study was that risks are portrayed differently than
benefits within online DTCPA. Because the FDA leaves online DTCPA somewhat
unregulated at the current time, pharmaceutical companies determine how to portray
risks and benefits on their websites. Researchers have an opportunity to show their
findings to policymakers and urge the FDA to force pharmaceutical companies to share
information on risks and side-effects in more prominent ways within DTCPA, parallel to
how benefits are portrayed.
The results of this study show that online DTCPA websites for traditional OCPs
define menstruation as problematic, and recommend these traditional OCPs as a
treatment for menstrual problems. When presented to prospective consumers, DTCPA
for traditional OCPs purposely does not include information about how many women
experience menstrual difficulties or what is “normal” about menstruation (and therefore
what should maybe be left untreated); instead the focus is on how OCPs can be a
treatment and solution to these vaguely defined menstrual difficulties. Yet, according to
the research literature, there are concerns that women might trivialize major menstrual
disorders, such as amenorrhea, that require medical intervention, if untreated (“normal”)
menstruation is always defined as something problematic (Johnston-Robledo, Barnack
& Wares, 2006). Concerns also exist that women might not be fully advised about the
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risks of managing menstruation through the use of OCPs (Society of Menstrual Cycle
Research, 2007). Furthermore, we lack research on the long-term risks associated with
using OCPs for menstrual management (Rako, 2006; Vanderhaeghe, 2011). There is
much still to research about the use of OCPs, and the DTCPA recommendations that
women receive about both menstruation (as a problem) and OCPs (as a form of
treatment for menstruation) should be of larger concern to us.
A future research study that shows women the contents of DTCPA websites for
traditional OCPs, and then collects their opinions and understandings of what is
presented, would be helpful in determining what prospective consumers are actually
learning about pregnancy prevention, menstrual management, traditional OCPs,
medicalization, healthcare providers, and other related subjects through DTCPA. A
long-term study that also looks at women who have used traditional OCPs primarily for
their menstrual benefits versus pregnancy prevention benefits can enhance our
knowledge about the use of traditional OCPs.
While previous studies have been completed on the nature of online DTCPA
websites for extended-cycle OCPs such as Seasonale, this study brings the focus back
to online DTCPA websites for traditional OCPs. In the future, more comparative analysis
of DTCPA for extended cycle and traditional OCPs should be undertaken as well,
because there has been little attempt to compare these two sets of OCPs so far.
DTCPA for other birth control methods has not been analyzed enough either, so varied
types of comparative research can be explored in the future.
The Internet has become another platform for DTCPA (Liang & Mackey, 2011).
One of the concerns about online DTCPA is that the Internet allows information to reach
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a very large number of people of all ages in a very short amount of time (Fox et al.,
2006). Online DTCPA is also unique, as prospective consumers are exposed to
information about prescription drugs around the clock and in the privacy of their own
homes, with no opportunity to engage more actively with the information that is
presented to them. Another important concern is that the information on the Internet is
often not monitored by the FDA, which makes online DTCPA different from other forms
of DTCPA (Woodlock, 2005). This provides pharmaceutical companies more freedom to
impart messages to online consumers. Because of these issues, online DTCPA
certainly warrants further research.
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APPENDIX
CODE SHEET
Categories Examined
1.

Color of the websites

2.

Presence of tabs for consumers

3.

Presence of tabs for health care providers

4.

Slogans on the websites

5.

Visual Imagery on the websites

6.

Videos on the websites

7.

Frequently Asked Questions

8.

Consumer Incentives for consumers and healthcare providers

9.

Types of benefits present on the websites

10.

Types of risks present on the websites

11.

Location of benefit and risk information on the websites

12.

Language surrounding benefit and risk information on the websites

13.

Medicalization on the websites – Naming the problem

14.

Medicalization on the websites– Treating the problem

15.

Medicalization on the websites - The role of healthcare providers

Categories Examined

Search terms/phrases/criteria

1. Color of the websites

Different colors – Yes/No
Main colors on the websites (list all)
Colors of the text on the websites (list all)
Frequency of color schemes
Frequency of colors present

2. Presence of tabs for

Tabs– Yes/No
Type of tabs present
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consumers

Frequency of consumer tabs in total
Function of tabs present – helping the consumer,
information providing to the consumer, encouraging the
consumer (check all that apply)

3. Presence of tabs for
healthcare providers

Tabs – Yes/No
Type of tabs present
Frequency of healthcare provider tabs in total
Function of tabs present – helping the healthcare
provider, information providing to the healthcare provider,
encouraging the healthcare provider to prescribe the
medication (check all that apply)

4. Slogans on the
websites

Messages that convey message of the product in a larger
font upon entry to the site – Yes/No
Frequency of slogans per website
Adjectives present (list all)
Cure mentioned – Yes/No

5. Visual Imagery on the Photos, diagrams, cartoons, silhouettes – Yes/No
websites
Product Imagery – Yes/No
Types of product imagery – Pill pack, pill box (check all
that apply)
Frequency of product images present
Is pill visible in the pill pack? Yes/No
People Imagery – Yes/No
Male and or female images – Yes/No
Race of people imagery – Caucasian, African-American,
Asian, South Asian, Hispanic
Location – Outdoor/Indoor
Location –Nature or not (list all if nature is present)
Actions being engaged in – Physical activities, Relaxing,
Smiling, laughing (list all)
Frequency of people images present
Other Imagery – Yes/No
Types of Other imagery
Location – Outdoor/Indoor
Actions being engaged in – Physical activities, Relaxing,
Smiling, laughing (list all)
Frequency of other images present
6. Videos on the
websites

Videos – Yes/No
Male and or female images – Yes/No
Location – Outdoor/Indoor
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Actions being engaged in – Physical activities, Relaxing,
Smiling, laughing (list all)
Frequency of images present in the videos
7. Frequently Asked
Questions

FAQ section – Yes/No
Frequency of FAQ sections per website
Types of questions present – help providing, product
encouraging (check all that apply)

8. Consumer Incentives

Consumer incentives for consumers – Present or Not
Consumer Incentives for healthcare providers – present
or Not
Frequency of incentives present for consumers and
healthcare providers
Description- “Coupon”, “% off”, “No more than”, “Savings”

9. Benefit information

Yes/No

Description - “Prevent”, “Prevention”, “birth control”,
10. Portrayal of
pregnancy prevention “contraceptive”, “approved to prevent pregnancy”,
“prescription birth control”
as a benefit
Frequency of this benefit for consumers
11. Portrayal of
menstrual benefits

Description – “Lighter”, “Shorter”, “Predictable”
Frequency of this benefit for consumers

12. Risk information

Yes/No

13. Portrayal of Smoking
risk

Description – “Warning”, “Smokers”
Frequency of this risk for consumers

14. Portrayal of other
risks/side-effects

Description – “Risks”, “Side effects”, “Other risks”, “other
side-effects”, “common risks”, “common side-effects”
Frequency of these risks for consumers

15. Location of benefit
and risk information

Location – Top of the page, middle of the page, bottom of
the page (check all that apply)

16. Medicalization –
Naming the problem

Description – “symptoms”, “heavy”, “long”, “lasts for”,
“pain”, “cramps”, “bleeding”, “normal”, “bleeding”, “loss”,
“discharge”, “expulsion”, “problem”, “unpredictable”,
“interfere”, “heavy”, “long”, “pain”, “unregulated (check all
that apply)
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17. Medicalization –
Treating the problem

Description - “treat”, “help”, “relief”, “clinically proven”,
“manage”, “reduce”, “shorter”, “lighter”, “regulate”,
“control”, “less than” (check all that apply)

18. Medicalization - The
role of healthcare
providers

Description – “ask”, “encourage”, “request”, “prescribe”,
provide”, “treat”, “help” (check all that apply)
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Internet Direct-to-consumer pharmaceutical advertising (DTCPA) continues to be
an important, popular and rising platform for pharmaceutical companies to market their
products to consumers. The purpose of this study was to determine how traditional oral
contraceptive pills (OCPs) are portrayed on the pharmaceutical websites during Internet
DTCPA. This study also looked to see how women’s bodies and the process of
menstruation were medicalized on these websites. Eight traditional OCP websites were
analyzed using a qualitative content analysis. The findings suggest that website
characteristics such as color, slogans, consumer incentives, images and videos are
created in a strategic manner to show consumers about the positive and fail-proof
aspects of the OCPs. Benefits such as pregnancy prevention, menstrual management
and low amount of hormones took priority over the risks/side-effects of OCPs on the
websites. The only risks/side-effects that were emphasized on the websites were the
warnings given to smokers who might be using the OCPs or will begin to use the OCPs.
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Medicalization was also present during the Internet DTCPA of traditional OCPs. The
results demonstrate that menstruation is defined through a symptomatic lens on the
websites as being heavy, long, unpredictable and painful. Treatment of menstruation is
encouraged to achieve main benchmarks such as a shorter period, a lighter period and
a more predicable period. The role of doctors continues to be that of experts who will
provide women with treatments using the OCPs to manage their menstrual cycles.
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